US20120309695A1 - Crystalline form of linaclotide - Google Patents
Crystalline form of linaclotide Download PDFInfo
- Publication number
- US20120309695A1 US20120309695A1 US13/586,303 US201213586303A US2012309695A1 US 20120309695 A1 US20120309695 A1 US 20120309695A1 US 201213586303 A US201213586303 A US 201213586303A US 2012309695 A1 US2012309695 A1 US 2012309695A1
- Authority
- US
- United States
- Prior art keywords
- linaclotide
- crystalline form
- diffraction pattern
- powder diffraction
- ray powder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- KXGCNMMJRFDFNR-WDRJZQOASA-N linaclotide Chemical compound C([C@H](NC(=O)[C@@H]1CSSC[C@H]2C(=O)N[C@H]3CSSC[C@H](N)C(=O)N[C@H](C(N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N2)=O)CSSC[C@H](NC(=O)[C@H](C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(N)=O)NC3=O)C(=O)N[C@H](C(NCC(=O)N1)=O)[C@H](O)C)C(O)=O)C1=CC=C(O)C=C1 KXGCNMMJRFDFNR-WDRJZQOASA-N 0.000 title claims abstract description 252
- 108010024409 linaclotide Proteins 0.000 title claims abstract description 252
- 229960000812 linaclotide Drugs 0.000 title claims abstract description 252
- 238000000034 method Methods 0.000 claims abstract description 37
- 238000000634 powder X-ray diffraction Methods 0.000 claims description 120
- 239000008194 pharmaceutical composition Substances 0.000 claims description 15
- 208000018522 Gastrointestinal disease Diseases 0.000 claims description 10
- 208000010643 digestive system disease Diseases 0.000 claims description 7
- 208000018685 gastrointestinal system disease Diseases 0.000 claims description 7
- 206010010774 Constipation Diseases 0.000 claims description 4
- 208000002551 irritable bowel syndrome Diseases 0.000 claims description 4
- 230000001684 chronic effect Effects 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 abstract description 13
- 239000000203 mixture Substances 0.000 description 89
- 239000000047 product Substances 0.000 description 74
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 28
- 230000007062 hydrolysis Effects 0.000 description 19
- 238000006460 hydrolysis reaction Methods 0.000 description 19
- 239000007857 degradation product Substances 0.000 description 18
- 239000000725 suspension Substances 0.000 description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 17
- 230000015572 biosynthetic process Effects 0.000 description 16
- 230000021736 acetylation Effects 0.000 description 15
- 238000006640 acetylation reaction Methods 0.000 description 15
- 239000000706 filtrate Substances 0.000 description 15
- 239000011521 glass Substances 0.000 description 15
- 150000001875 compounds Chemical class 0.000 description 14
- 230000001404 mediated effect Effects 0.000 description 13
- 230000003647 oxidation Effects 0.000 description 13
- 238000007254 oxidation reaction Methods 0.000 description 13
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 12
- 230000006240 deamidation Effects 0.000 description 12
- 230000022244 formylation Effects 0.000 description 12
- 238000006170 formylation reaction Methods 0.000 description 12
- 239000000243 solution Substances 0.000 description 12
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- 239000011260 aqueous acid Substances 0.000 description 9
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 7
- 239000002552 dosage form Substances 0.000 description 7
- 238000009472 formulation Methods 0.000 description 7
- 241000894007 species Species 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 6
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 6
- 239000000654 additive Substances 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 238000000589 high-performance liquid chromatography-mass spectrometry Methods 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 4
- 239000000539 dimer Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 4
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 4
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 3
- 238000001157 Fourier transform infrared spectrum Methods 0.000 description 3
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 3
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 229920001903 high density polyethylene Polymers 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 239000004700 high-density polyethylene Substances 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 229940098779 methanesulfonic acid Drugs 0.000 description 3
- 229910017604 nitric acid Inorganic materials 0.000 description 3
- 239000006186 oral dosage form Substances 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 102100034605 Atrial natriuretic peptide receptor 3 Human genes 0.000 description 2
- 239000005711 Benzoic acid Substances 0.000 description 2
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- 101000924488 Homo sapiens Atrial natriuretic peptide receptor 3 Proteins 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 235000003704 aspartic acid Nutrition 0.000 description 2
- 235000010233 benzoic acid Nutrition 0.000 description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 238000007405 data analysis Methods 0.000 description 2
- 238000013480 data collection Methods 0.000 description 2
- 238000000113 differential scanning calorimetry Methods 0.000 description 2
- 238000001938 differential scanning calorimetry curve Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000011067 equilibration Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- -1 for example Chemical class 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 2
- 235000006408 oxalic acid Nutrition 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 238000004007 reversed phase HPLC Methods 0.000 description 2
- 238000004611 spectroscopical analysis Methods 0.000 description 2
- 239000001384 succinic acid Substances 0.000 description 2
- 235000011044 succinic acid Nutrition 0.000 description 2
- 238000002411 thermogravimetry Methods 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- OCKGFTQIICXDQW-ZEQRLZLVSA-N 5-[(1r)-1-hydroxy-2-[4-[(2r)-2-hydroxy-2-(4-methyl-1-oxo-3h-2-benzofuran-5-yl)ethyl]piperazin-1-yl]ethyl]-4-methyl-3h-2-benzofuran-1-one Chemical compound C1=C2C(=O)OCC2=C(C)C([C@@H](O)CN2CCN(CC2)C[C@H](O)C2=CC=C3C(=O)OCC3=C2C)=C1 OCKGFTQIICXDQW-ZEQRLZLVSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- PLTGTJAZQRGMPP-FXQIFTODSA-N Asn-Pro-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CC(N)=O PLTGTJAZQRGMPP-FXQIFTODSA-N 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- MZEFYWUUHCGAIS-UHFFFAOYSA-N C1SSCC123(CSSC2)CSSC3 Chemical compound C1SSCC123(CSSC2)CSSC3 MZEFYWUUHCGAIS-UHFFFAOYSA-N 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- ISWAQPWFWKGCAL-ACZMJKKPSA-N Cys-Cys-Glu Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(O)=O)C(O)=O ISWAQPWFWKGCAL-ACZMJKKPSA-N 0.000 description 1
- ALNKNYKSZPSLBD-ZDLURKLDSA-N Cys-Thr-Gly Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(O)=O ALNKNYKSZPSLBD-ZDLURKLDSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 238000004566 IR spectroscopy Methods 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000030053 Opioid-Induced Constipation Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000286209 Phasianidae Species 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 238000001069 Raman spectroscopy Methods 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- CGDZGRLRXPNCOC-SRVKXCTJSA-N Tyr-Cys-Cys Chemical compound SC[C@@H](C(O)=O)NC(=O)[C@H](CS)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 CGDZGRLRXPNCOC-SRVKXCTJSA-N 0.000 description 1
- 238000002441 X-ray diffraction Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 108010010430 asparagine-proline-alanine Proteins 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 239000007894 caplet Substances 0.000 description 1
- 238000002144 chemical decomposition reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 108010069495 cysteinyltyrosine Proteins 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 229910003460 diamond Inorganic materials 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- 238000002050 diffraction method Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 239000007897 gelcap Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 229910052738 indium Inorganic materials 0.000 description 1
- APFVFJFRJDLVQX-UHFFFAOYSA-N indium atom Chemical compound [In] APFVFJFRJDLVQX-UHFFFAOYSA-N 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000001565 modulated differential scanning calorimetry Methods 0.000 description 1
- 210000004985 myeloid-derived suppressor cell Anatomy 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 150000003873 salicylate salts Chemical class 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000011285 therapeutic regimen Methods 0.000 description 1
- 238000001757 thermogravimetry curve Methods 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
Definitions
- the present invention relates to a novel ⁇ -crystalline form of linaclotide, as well as processes for the preparation of the ⁇ -crystalline form, compositions comprising the ⁇ -crystalline form, and methods of using the ⁇ -crystalline form.
- U.S. Pat. No. 7,304,036 discloses peptides that act as agonists of the guanylate cyclase C (GC—C) receptor for the treatment of gastrointestinal disorders.
- GC—C guanylate cyclase C
- One particular peptide disclosed therein is linaclotide, which consists of the following amino acid sequence: Cys Cys Glu Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr.
- U.S. Pat. Nos. 7,304,036 and 7,371,727 disclose methods for the preparation of linaclotide and related peptides.
- the contents of U.S. Pat. Nos. 7,304,036 and 7,371,727 are incorporated herein by reference, in their entirety.
- the present invention relates to a new crystalline form or polymorph of linaclotide, which has surprisingly and unexpectedly enhanced properties, such as enhanced or greater stability, as compared to amorphous linaclotide.
- a crystalline form of linaclotide may have enhanced storage stability and enhanced stability against chemical degradation as compared to amorphous linaclotide.
- the present invention relates to a novel ⁇ -crystalline form of linaclotide.
- Various methods and processes for the preparation and use of the crystalline form are also described herein.
- FIG. 1 shows the X-ray powder diffraction pattern of amorphous linaclotide.
- FIG. 2 shows the X-ray powder diffraction pattern of an ⁇ -crystalline form of linaclotide.
- FIG. 3 shows the X-ray powder diffraction pattern of an ⁇ -crystalline form of linaclotide.
- FIG. 4 shows the Fourier Transform infrared spectrum of an ⁇ -crystalline form of linaclotide.
- FIG. 5 shows a differential scanning calorimetry (DSC) thermogram of an ⁇ -crystalline form of linaclotide.
- FIG. 6 shows the X-ray powder diffraction pattern of an ⁇ -crystalline form of linaclotide.
- FIG. 7 shows the X-ray powder diffraction pattern of an ⁇ -crystalline form of linaclotide.
- FIG. 8 shows the X-ray powder diffraction pattern of an ⁇ -crystalline form of linaclotide.
- FIG. 9 shows the X-ray powder diffraction pattern of an ⁇ -crystalline form of linaclotide.
- FIG. 10 shows the X-ray powder diffraction pattern of an ⁇ -crystalline form of linaclotide.
- FIG. 11 shows the X-ray powder diffraction pattern of an ⁇ -crystalline form of linaclotide.
- FIG. 12 shows the X-ray powder diffraction pattern of an ⁇ -crystalline form of linaclotide.
- FIG. 13 shows the X-ray powder diffraction pattern of an ⁇ -crystalline form of linaclotide.
- the present invention provides crystalline forms of linaclotide.
- the methods for preparation as disclosed in U.S. Pat. Nos. 7,304,036 and 7,371,727 yield linaclotide in an amorphous state.
- the X-ray powder diffraction pattern of amorphous linaclotide is illustrated in FIG. 1 .
- the present invention relates to crystalline forms of linaclotide, specifically ⁇ -crystalline forms of linaclotide ( ⁇ form linaclotide).
- the ⁇ form linaclotide is characterized by an X-ray powder diffraction pattern comprising a peak at about 6.2+/ ⁇ 0.5 degrees 2 ⁇ .
- the ⁇ form linaclotide is characterized by an X-ray powder diffraction pattern comprising a peak at about 7.8+/ ⁇ 0.5 degrees 2 ⁇ .
- the ⁇ form linaclotide is characterized by an X-ray powder diffraction pattern comprising a peak at about 8.6+/ ⁇ 0.5 degrees 2 ⁇ .
- the ⁇ form linaclotide is characterized by an X-ray powder diffraction pattern comprising a peak at about 9.7+/ ⁇ 0.5 degrees 2 ⁇ .
- the ⁇ form linaclotide is characterized by an X-ray powder diffraction pattern comprising a peak at about 10.3+/ ⁇ 0.5 degrees 2 ⁇ .
- the ⁇ form linaclotide is characterized by an X-ray powder diffraction pattern comprising a peak at about 11.4+/ ⁇ 0.5 degrees 2 ⁇ .
- the ⁇ form linaclotide is characterized by an X-ray powder diffraction pattern comprising a peak at about 14.3+/ ⁇ 0.5 degrees 2 ⁇ .
- the ⁇ form linaclotide is characterized by an X-ray powder diffraction pattern comprising a peak at about 16.0+/ ⁇ 0.5 degrees 2 ⁇ .
- the ⁇ form linaclotide is characterized by an X-ray powder diffraction pattern comprising a peak at about 17.9+/ ⁇ 0.5 degrees 2 ⁇ .
- the ⁇ form linaclotide is characterized by an X-ray powder diffraction pattern comprising a peak at about 19.5+/ ⁇ 0.5 degrees 2 ⁇ .
- the ⁇ form linaclotide is characterized by an X-ray powder diffraction pattern comprising a peak at about 20.9+/ ⁇ 0.5 degrees 2 ⁇ .
- the ⁇ form linaclotide is characterized by an X-ray powder diffraction pattern comprising a peak at about 21.6+/ ⁇ 0.5 degrees 2 ⁇ .
- the ⁇ form linaclotide is characterized by an X-ray powder diffraction pattern comprising a peak at about 22.6+/ ⁇ 0.5 degrees 2 ⁇ .
- the ⁇ form linaclotide is characterized by an X-ray powder diffraction pattern comprising a peak at about 23.9+/ ⁇ 0.5 degrees 2 ⁇ .
- the ⁇ form linaclotide is characterized by an X-ray powder diffraction pattern comprising a peak at about 24.4+/ ⁇ 0.5 degrees 2 ⁇ .
- the ⁇ form linaclotide is characterized by an X-ray powder diffraction pattern comprising a peak at about 25.2+/ ⁇ 0.5 degrees 2 ⁇ .
- the ⁇ form linaclotide is characterized by an X-ray powder diffraction pattern comprising peaks at about 6.2, about 7.8, about 11.4, about 16.0, about 19.5, and at about 23.9+/ ⁇ 0.5 degrees 2 ⁇ .
- the ⁇ form linaclotide is characterized by an X-ray powder diffraction pattern comprising peaks at about 6.2, about 7.8, about 8.6, about 9.7, about 10.3, about 11.4, about 14.3, about 16.0, about 17.9, about 19.5, about 20.9, about 21.6, about 22.6, about 23.9, about 24.4, and at about 25.2+/ ⁇ 0.5 degrees 2 ⁇ .
- the ⁇ form linaclotide is characterized by an X-ray powder diffraction pattern comprising peaks at about 6.2 and at about 7.8+/ ⁇ 0.5 degrees 2 ⁇ . In exemplary embodiments, the ⁇ form linaclotide is characterized by an X-ray powder diffraction pattern comprising peaks at about 7.8 and at about 23.9+/ ⁇ 0.5 degrees 2 ⁇ . In exemplary embodiments, the ⁇ form linaclotide is characterized by an X-ray powder diffraction pattern comprising peaks at about 6.2, about 7.8 and about 23.9 +/ ⁇ 0.5 degrees 2 ⁇ .
- the ⁇ form linaclotide is characterized by an X-ray powder diffraction pattern comprising peaks at about 6.2, about 7.8, about 19.5 and about 23.9+/ ⁇ 0.5 degrees 2 ⁇ . In exemplary embodiments, the ⁇ form linaclotide is characterized by an X-ray powder diffraction pattern comprising peaks at about 6.2, about 7.8, about 22.6 and about 23.9+/ ⁇ 0.5 degrees 2 ⁇ .
- the ⁇ form linaclotide is characterized by an X-ray powder diffraction pattern comprising peaks at about 6.2, about 7.8, about 23.9+/ ⁇ 0.5 degrees 2 ⁇ and optionally one or more peaks at about 19.5+/ ⁇ 0.5 degrees 2 ⁇ and/or about 22.6+/ ⁇ 0.5 degrees 2 ⁇ .
- the ⁇ form linaclotide is characterized by an X-ray powder diffraction pattern comprising peaks at about 6.2, about 7.8, about 19.5, about 22.6 and about 23.9+/ ⁇ 0.5 degrees 2 ⁇ .
- the ⁇ form linaclotide is characterized by an X-ray powder diffraction pattern substantially as shown in FIG. 2 or FIG. 3 .
- the ⁇ form linaclotide is characterized by an X-ray powder diffraction pattern comprising one or more peaks as provided in Table 1. In some embodiments, the ⁇ form linaclotide is characterized by an X-ray powder diffraction pattern comprising one or more peaks at about 5.7, about 7.7, about 23.8+/ ⁇ 0.5 degrees 2 ⁇ and optionally one or more peaks at about 7.0, about 8.5, about 9.6, about 10.2, about 11.3, about 12.6, about 13.7, about 14.3, about 15.5, about 16.4, about 17.1, about 17.9, about 18.5, about 19.4, about 20.8, about 21.5, about 22.5, about 23.1, about 24.5, about 25.5, about 26.1, about 27.5, about 28.2, about 28.8 and/or about 29.6+/ ⁇ 0.5 degrees 2 ⁇ .
- the phrase “one or more peaks” should be understood to be inclusive of (i) crystalline forms that have XRD peaks at every peak value recited after this phrase, (ii) crystalline forms that have an XRD peak at only one of the peak values recited after this phrase, as well (iii) crystalline forms that have XRD peaks at two or more (e.g., three or more, four or more, five or more, six or more, or even seven or more) of the peak values recited after this phrase.
- the ⁇ form linaclotide is characterized by an X-ray powder diffraction pattern comprising peaks at about 5.7 and about 7.7+/ ⁇ 0.5 degrees 2 ⁇ . In some embodiments, the ⁇ form linaclotide is characterized by an X-ray powder diffraction pattern comprising peaks at about 5.7, about 7.7 and about 23.8+/ ⁇ 0.5 degrees 2 ⁇ .
- the ⁇ form linaclotide is characterized by an X-ray powder diffraction pattern comprising peaks at about 5.7, about 7.7, about 23.8+/ ⁇ 0.5 degrees 2 ⁇ and optionally one or more peaks at about 19.4+/ ⁇ 0.5 degrees 2 ⁇ and/or at about 22.5+/ ⁇ 0.5 degrees 2 ⁇ .
- the ⁇ form linaclotide is characterized by an X-ray powder diffraction pattern comprising peaks at about 5.7, about 7.7, about 19.4 and about 23.8+/ ⁇ 0.5 degrees 2 ⁇ .
- the ⁇ form linaclotide is characterized by an X-ray powder diffraction pattern comprising peaks at about 5.7, about 7.7, about 22.5 and about 23.8+/ ⁇ 0.5 degrees 2 ⁇ . In some embodiments, the ⁇ form linaclotide is characterized by an X-ray powder diffraction pattern comprising peaks at about 5.7, about 7.7, about 19.4, about 22.5 and about 23.8+/ ⁇ 0.5 degrees 2 ⁇ .
- the ⁇ form linaclotide is characterized by an X-ray powder diffraction pattern substantially as shown in FIG. 6 . In some embodiments, the ⁇ form linaclotide is characterized by an X-ray powder diffraction pattern comprising one or more peaks as provided in Table 2.
- a crystalline form of linaclotide wherein the crystalline form has an X-ray powder diffraction pattern comprising peaks at about 5.7, about 7.7 and about 23.8+/ ⁇ 0.5 degrees 2 ⁇ and optionally one or more peaks at about 6.3, about 8.4, about 9.5, about 10.5, about 11.7, about 12.4, about 13.6, about 14.7, about 15.4, about 17.0, about 17.8, about 19.6, about 20.6, about 21.3, about 22.5, about 24.4, about 25.1, about 26.5, about 27.1, about 27.7, and/or about 28.7+/ ⁇ 0.5 degrees 2 ⁇ .
- the ⁇ form linaclotide is characterized by an X-ray powder diffraction pattern substantially as shown in FIG. 7 .
- a crystalline form of linaclotide is provided, wherein the crystalline form has an X-ray powder diffraction pattern comprising one or more peaks as provided in Table 3.
- a crystalline form of linaclotide wherein the crystalline form has an X-ray powder diffraction pattern comprising peaks at about 5.8, about 7.7 and about 23.9+/ ⁇ 0.5 degrees 2 ⁇ and optionally one or more peaks at about 6.4, about 8.4, about 9.4, about 10.5, about 11.5, about 12.9, about 13.6, about 14.9, about 15.9, about 17.4, about 18.2, about 18.8, about 19.4, about 20.4, about 22.5, about 23.3 and/or about 25.7+/ ⁇ 0.5 degrees 2 ⁇ .
- the ⁇ form linaclotide is characterized by an X-ray powder diffraction pattern substantially as shown in FIG. 8 .
- a crystalline form of linaclotide is provided, wherein the crystalline form has an X-ray powder diffraction pattern comprising one or more peaks as provided in Table 4.
- a crystalline form of linaclotide wherein the crystalline form has an X-ray powder diffraction pattern comprising one or more peaks at about 5.6, about 7.7, about 23.8 and optionally one or more peaks at about 8.4, about 9.5, about 10.1, about 11.0, about 11.8, about 12.2, about 14.1, about 14.9, about 15.4, about 16.3, about 17.0, about 17.8, about 18.7, about 19.4, about 20.7, about 21.5, about 22.5, about 24.4 and/or about 25.4+/ ⁇ 0.5 degrees 2 ⁇ .
- the ⁇ form linaclotide is characterized by an X-ray powder diffraction pattern substantially as shown in FIG. 9 .
- a crystalline form of linaclotide is provided, wherein the crystalline form has an X-ray powder diffraction pattern comprising one or more peaks as provided in Table 5.
- a crystalline form of linaclotide wherein the crystalline form has an X-ray powder diffraction pattern comprising peaks at about 7.7, about 23.8+/ ⁇ 0.5 degrees 2 ⁇ and optionally one or more peaks at about 5.6, about 9.5, about 10.1, about 11.0, about 11.8, about 12.5, about 14.1, about 14.9, about 15.9, about 17.0, about 17.8, about 19.4, about 20.2, about 20.7, about 21.1, about 21.5, about 22.5, about 23.1, about 24.4, about 25.4, and/or about 27.1+/ ⁇ 0.5 degrees 2 ⁇ .
- the ⁇ form linaclotide is characterized by an X-ray powder diffraction pattern substantially as shown in FIG. 10 .
- a crystalline form of linaclotide is provided, wherein the crystalline form has an X-ray powder diffraction pattern comprising one or more peaks as provided in Table 6.
- a crystalline form of linaclotide wherein the crystalline form has an X-ray powder diffraction pattern comprising peaks at about 5.6 and about 7.7+/ ⁇ 0.5 degrees 2 ⁇ and optionally one or more peaks at about 8.5, about 10.2, about 11.2, about 12.3, about 13.7, about 16.0, about 17.9, about 19.5, about 20.4, about 22.5, about 23.8 about 25.5, about 27.3, and/or about 27.6+/ ⁇ 0.5 degrees 2 ⁇ .
- the ⁇ form linaclotide is characterized by an X-ray powder diffraction pattern substantially as shown in FIG. 11 .
- a crystalline form of linaclotide is provided, wherein the crystalline form has an X-ray powder diffraction pattern comprising one or more peaks as provided in Table 7.
- a crystalline form of linaclotide wherein the crystalline form has an X-ray powder diffraction pattern comprising one or more peaks at about 5.6, about 6.0, about 6.3, about 7.7, about 8.1, about 8.4, about 9.5, about 10.1, about 11.0, about 11.2, about 11.8, about 12.2, about 12.5, about 13.6, about 14.2, about 14.9, about 15.4, about 15.9, about 16.3, about 17.0, about 17.8, about 18.9, about 19.4, about 20.2, about 20.7, about 21.4, about 22.4, about 23.8, about 24.4 and/or about 25.4+/ ⁇ 0.5 degrees 2 ⁇ .
- the ⁇ form linaclotide is characterized by an X-ray powder diffraction pattern substantially as shown in FIG. 12 .
- a crystalline form of linaclotide is provided, wherein the crystalline form has an X-ray powder diffraction pattern comprising one or more peaks as provided in Table 8.
- a crystalline form of linaclotide wherein the crystalline form has an X-ray powder diffraction pattern comprising one or more peaks at about 5.6, about 6.3, about 7.7, about 8.5, about 9.5, about 10.6, about 11.2, about 12.1, about 13.6, about 14.6, about 15.4, about 16.3, about 17.0, about 17.8, about 19.3, about 20.7, about 21.5, about 22.5, about 23.1, about 23.7 and/or about 25.3+/ ⁇ 0.5 degrees 2 ⁇ .
- the ⁇ form linaclotide is characterized by an X-ray powder diffraction pattern substantially as shown in FIG. 13 .
- a crystalline form of linaclotide is provided, wherein the crystalline form has an X-ray powder diffraction pattern comprising one or more peaks as provided in Table 9.
- a crystalline form of linaclotide wherein the crystalline form has an X-ray powder diffraction pattern comprising one or more peaks at about 5.6, about 7.0, about 7.7, about 8.4, about 9.5, about 10.1, about 11.2, about 12.4, about 13.6, about 14.6, about 15.8, about 16.6, about 18.0, about 18.9, about 19.7, about 20.7, about 21.4, about 22.4, about 23.0, about 24.1 and/or about 25.0+/ ⁇ 0.5 degrees 2 ⁇ .
- ⁇ form linaclotide is characterized by an X-ray powder diffraction pattern comprising peaks having d-spacing values at about 3.7, about 11.5, and about 15.5+/ ⁇ 0.5 angstroms ( ⁇ ). In some embodiments, ⁇ form linaclotide is characterized by an X-ray powder diffraction pattern comprising peaks having d-spacing values at about 3.7, about 4.5, about 11.5, and about 15.5+/ ⁇ 0.5 angstroms ( ⁇ ).
- the X-ray powder diffraction peaks recited herein for particular embodiments can vary by ⁇ 0.4 degrees 2 ⁇ , by ⁇ 0.3 degrees 2 ⁇ , by ⁇ 0.2 degrees 2 ⁇ , or even by ⁇ 0.1 degrees 2 ⁇ .
- a crystalline form of linaclotide is provided having an X-ray power diffraction pattern comprising peaks at about 5.7, about 7.7 and about 23.8+/ ⁇ 0.3 degrees 2 ⁇ .
- ⁇ form linaclotide is characterized by an X-ray powder diffraction pattern comprising peaks having d-spacing values at about 1.4, about 1.1, about 1.0, about 0.9, about 0.8, about 0.6, about 0.5 and about 0.4+/ ⁇ 3% nm.
- the ⁇ form linaclotide is characterized by an X-ray powder diffraction pattern comprising d-spacing values at about 1.4, about 1.1, about 0.8, about 0.6, about 0.5 and about 0.4+/ ⁇ 3% nm.
- the ⁇ form linaclotide is characterized by an X-ray powder diffraction pattern comprising a d-spacing value at about 1.4+/ ⁇ 3% nm.
- the ⁇ form linaclotide is characterized by an X-ray powder diffraction pattern comprising a d-spacing value at about 1.1+/ ⁇ 3% nm.
- the ⁇ form linaclotide is characterized by an X-ray powder diffraction pattern comprising a d-spacing value at about 1.0+/ ⁇ 3% nm.
- the ⁇ form linaclotide is characterized by an X-ray powder diffraction pattern comprising a d-spacing value at about 0.9+/ ⁇ 3% nm.
- the ⁇ form linaclotide is characterized by an X-ray powder diffraction pattern comprising a d-spacing value at about 0.8+/ ⁇ 3% nm.
- the ⁇ form linaclotide is characterized by an X-ray powder diffraction pattern comprising a d-spacing value at about 0.6+/ ⁇ 3% nm.
- the ⁇ form linaclotide is characterized by an X-ray powder diffraction pattern comprising a d-spacing value at about 0.5+/ ⁇ 3% nm.
- the ⁇ form linaclotide is characterized by an X-ray powder diffraction pattern comprising a d-spacing value at about 0.4+/ ⁇ 3% nm.
- the ⁇ form linaclotide is characterized by a Fourier Transform infrared spectrum substantially as shown in FIG. 4 .
- the ⁇ form linaclotide is characterized by a DSC thermogram substantially as shown in FIG. 5 .
- the present invention provides processes for preparing the ⁇ -crystalline forms of linaclotide described herein.
- methods for manufacturing a medicament comprising ⁇ form linaclotide that are useful in the treatment of a gastrointestinal disorder are provided.
- ⁇ form linaclotide is produced by crystallizing linaclotide to form ⁇ form linaclotide and optionally isolating the ⁇ form linaclotide.
- ⁇ form linaclotide is prepared by crystallizing linaclotide in an aqueous acid solution and optionally isolating the ⁇ -crystalline form of linaclotide.
- Any suitable aqueous acid solution can be used in this regard, such as, for example, any solution of acid in water at various strengths or concentrations.
- Such acids may include, but are not limited to, hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, methane sulfonic acid, phosphoric acid, acetic acid, lactic acid, p-toluene sulfonic acid, oxalic acid, glutamic acid, fumaric acid, malic acid, aspartic acid, ascorbic acid, benzoic acid, maleic acid and succinic acid.
- the aqueous acid solution is selected from hydrochloric acid, hydrobromic acid, nitric acid, methane sulfonic acid, acetic acid, lactic acid, p-toluene sulfonic acid, oxalic acid, glutamic acid, aspartic acid, ascorbic acid, benzoic acid and succinic acid.
- the ⁇ -crystalline form of linaclotide can be identified, distinguished, and separated from amorphous linaclotide in any suitable manner, such as on the basis of differences in the diffraction, thermal and/or spectroscopic properties of these different forms of linaclotide.
- suitable such methods include, for example, X-ray powder diffractometry, capillary melting point determination, thermogravimetric analysis (TGA), differential scanning calorimetry (DSC) and/or spectroscopic methodologies (such as Raman spectroscopy and/or infrared (IR) spectroscopy).
- the relative intensities and positions of the peaks obtained by X-ray powder diffraction may vary depending upon, inter alia, the sample preparation technique, the sample mounting procedure, and the particular instrument employed.
- the listed X-ray powder diffraction pattern peaks for the crystalline form of linaclotide is about +/ ⁇ 0.2 degrees 2 ⁇ .
- the ⁇ form linaclotide can have any desired degree of purity, relative to other substances or components in the preparation.
- the present invention provides an ⁇ -crystalline form of linaclotide that is substantially pure, such as, for example, having greater than 40%, greater than 50%, greater than 60%, greater than 70%, greater than 80%, greater than 85%, greater than 90%, greater than 95%, greater than 96%, greater than 97%, greater than 98%, greater than 99%, greater than 99.2%, greater than 99.4%, greater than 99.6%, greater than 99.6%, or even greater than 99.9% purity, relative to other substances or components in the preparation.
- the ⁇ form linaclotide is about 45% to 95% pure, such as, for example, about 50% to 95% pure, about 55% to 90% pure, about 60% to 95% pure, or even about 70% to 99% pure, relative to other substances or components in the preparation. In some embodiments, the ⁇ form linaclotide is about 95% to 99% pure. In some embodiments, the ⁇ form linaclotide is about 90% to 95% pure. In some embodiments, the ⁇ form linaclotide is about 85% to 90% pure. In some embodiments, the ⁇ form linaclotide is about 80% to 85% pure. In some embodiments, the ⁇ form linaclotide is about 75% to 80% pure.
- the ⁇ form linaclotide is about 70% to 75% pure. In certain embodiments, the ⁇ form linaclotide is about 65% to 70% pure. In some embodiments, the ⁇ form linaclotide is about 60% to 65% pure. In other embodiments, the ⁇ form linaclotide is about 55% to 60% pure. In yet other embodiments, the ⁇ form linaclotide is about 50% to 55% pure. In some embodiments, the ⁇ form linaclotide is about 45% to 50% pure.
- the present invention provides a composition, formulation, or dosage form that comprises ⁇ form linaclotide and optional additional components, additives and/or species, such as, for example one or more ion species that interact with linaclotide.
- Such additional components, additives, and/or species can be administered alone or as an active ingredient of the composition, formulation, or dosage form. Moreover, the additional components, additives, and/or species can be administered before, after, and/or concurrently with ⁇ form linaclotide.
- the additional components, additives, and/or species are administered separately to a patient or subject (e.g., in a separate formulation or dosage form) from the ⁇ form linaclotide.
- the optional additional components, additives, and/or species comprise an active component of the formulation.
- the optional components comprise one or more pharmaceutically-acceptable carriers and/or excipients.
- the present invention provides a composition comprising ⁇ form linaclotide and a degradation product, such as a hydrolysis product, acetylation product, a formylation product, an oxidation product, a water-mediated degradation product, and/or a deamidation product.
- a degradation product such as a hydrolysis product, acetylation product, a formylation product, an oxidation product, a water-mediated degradation product, and/or a deamidation product.
- the composition can contain any desired purity relative to hydrolysis product(s).
- the composition comprises less than about 10% by weight of hydrolysis product(s), relative to the total weight of the composition, such as, for example, less than about 7.5 wt. %, less than about 5 wt. %, or even less than about 2 wt. % of hydrolysis product(s).
- the composition comprises from about 0.05% to about 5% by weight of hydrolysis product(s).
- the composition comprises from about 0.05% to about 2% by weight of the hydrolysis product(s).
- the composition may comprise from about 0.1% to about 2% by weight of the hydrolysis product(s).
- the composition can contain any desired purity relative to acetylation product(s).
- the acetylation product may comprise less than 10% by weight of the composition.
- the acetylation product may comprise less than 7.5% by weight of the composition.
- the acetylation product may comprise less than 5% by weight of the composition.
- the acetylation product may comprise less than 2% by weight of the composition.
- the acetylation product may comprise less than 1% by weight of the composition.
- the acetylation product may comprise less than 0.5% by weight of the composition.
- the acetylation product may comprise from about 0.05% to about 5% by weight of the composition. In some embodiments, the acetylation product may comprise from about 0.05% to about 2% by weight of the composition. In other embodiments, the acetylation product may comprise from about 0.1% to about 2% by weight of the composition. In yet other embodiments, the acetylation product may comprise from about 0.1% to about 2% by weight of the composition.
- the composition can contain any desired purity relative to formylation product(s).
- the formylation product may comprise less than 10% by weight of the composition.
- the formylation product may comprise less than 7.5% by weight of the composition.
- the formylation product may comprise less than 5% by weight of the composition.
- the formylation product may comprise less than 2% by weight of the composition.
- the formylation product may comprise from about 0.05% to about 5% by weight of the composition.
- the formylation product may comprise from about 0.05% to about 2% by weight of the composition.
- the formylation product may comprise from about 0.1% to about 2% by weight of the composition.
- the composition can contain any desired purity relative to oxidation product(s).
- the oxidation product may comprise less than 10% by weight of the composition. In some embodiments, the oxidation product may comprise less than 7.5% by weight of the composition. In some embodiments, the oxidation product may comprise less than 5% by weight of the composition. In other embodiments, the oxidation product may comprise less than 2% by weight of the composition. In still other embodiments, the oxidation product may comprise from about 0.05% to about 5% by weight of the composition. In exemplary embodiments, the oxidation product may comprise from about 0.05% to about 2% by weight of the composition. In yet other embodiments, the oxidation product may comprise from about 0.1% to about 2% by weight of the composition.
- the composition can contain any desired purity relative to water-mediated degradation product(s).
- the water-mediated degradation product(s) may comprise less than 10% by weight of the composition. In some embodiments, the water-mediated degradation product(s) may comprise less than 7.5% by weight of the composition. In some embodiments, the water-mediated degradation product(s) may comprise less than 5% by weight of the composition. In other embodiments, the water-mediated degradation product(s) may comprise less than 2% by weight of the composition. In still other embodiments, the water-mediated degradation product(s) may comprise from about 0.05% to about 5% by weight of the composition. In exemplary embodiments, the water-mediated degradation product(s) may comprise from about 0.05% to about 2% by weight of the composition. In yet other embodiments, the water-mediated degradation product(s) may comprise from about 0.1% to about 2% by weight of the composition.
- the composition can contain any desired purity relative to deamidation product(s).
- the deamidation product may comprise less than 10% by weight of the composition. In some embodiments, the deamidation product may comprise less than 7.5% by weight of the composition. In some embodiments, the deamidation product may comprise less than 5% by weight of the composition. In other embodiments, the deamidation product may comprise less than 2% by weight of the composition. In still other embodiments, the deamidation product may comprise from about 0.05% to about 5% by weight of the composition. In exemplary embodiments, the deamidation product may comprise from about 0.05% to about 2% by weight of the composition. In yet other embodiments, the deamidation product may comprise from about 0.1% to about 2% by weight of the composition.
- the invention provides a composition comprising ⁇ form linaclotide and less than 10 wt. % (such as less than 8 wt. %, less than 6 wt. %, less than 5 wt. %, less than 4 wt. %, less than 3 wt. %, less than 2 wt. %, less than 1 wt. %, less than 0.5 wt. %, or even less than 0.25 wt. %) of a combined total of a degradation product, such as a hydrolysis product, a formylation product, an oxidation product, a water-mediated degradation product, and/or a deamidation product.
- a degradation product such as a hydrolysis product, a formylation product, an oxidation product, a water-mediated degradation product, and/or a deamidation product.
- the invention provides a composition comprising ⁇ form linaclotide and less than 20 wt. % (such as less than 18 wt. %, less than 16 wt. %, less than 14 wt. %, less than 12 wt. %, less than 10 wt. %, less than 8 wt. %, less than 6 wt. %, less than 5 wt. %, less than 4 wt. %, less than 3 wt. %, less than 2 wt. %, less than 1 wt. %, less than 0.5 wt. %, or even less than 0.25 wt. %) of a combined total of a degradation product, such as a hydrolysis product, an acetylation product, a formylation product, an oxidation product, a water-mediated degradation product, and/or a deamidation product.
- a degradation product such as a hydrolysis product, an acetylation product,
- the present invention provides a composition comprising ⁇ form linaclotide and multimers.
- the multimers may be formed due to disulfide linkages.
- the multimers may be formed due to non-disulfide linkages.
- the composition may contain any desired purity relative to multimers.
- the composition comprises less than about 20 wt. % of multimers, such as, for example, less than about 18 wt. %, less than about 16 wt. %, less than about 14 wt. %, less than about 12 wt. %, less than about 10 wt. %, less than about 8 wt. %, less than about 6 wt.
- the compositions may comprise ⁇ form linaclotide and a dimer.
- the composition comprises less than about 20 wt. % of dimers, such as, for example, less than about 18 wt. %, less than about 16 wt. %, less than about 14 wt. %, less than about 12 wt. %, less than about 10 wt. %, less than about 8 wt. %, less than about 6 wt. %, less than about 5 wt. %, less than about 4 wt. %, less than about 3 wt. %, less than about 2 wt. %, less than about 1 wt. %, less than about 0.5 wt. %, or even less than about 0.1 wt. % of dimers.
- the present invention provides a composition comprising ⁇ form linaclotide and an isomer.
- the composition comprises less than about 20 wt. % of isomers, such as, for example, less than about 18 wt. %, less than about 16 wt. %, less than about 14 wt. %, less than about 12 wt. %, less than about 10 wt. %, less than about 8 wt. %, less than about 6 wt. %, less than about 5 wt. %, less than about 4 wt. %, less than about 3 wt. %, less than about 2 wt. %, less than about 1 wt. %, less than about 0.5 wt. %, or even less than about 0.1 wt. % of isomers.
- the present invention provides a composition comprising ⁇ form linaclotide and less than about 40 wt %, such as less than about 30 wt. %, less than about 20 wt. %, less than about 15 wt. %, less than about 10 wt. %, less than about 8 wt. %, less than about 6 wt. %, less than about 5 wt. %, less than about 4 wt. %, less than about 3 wt. %, less than about 2 wt. %, less than about 1 wt. %, less than about 0.5 wt. %, less than about 0.1 wt. %, or even less than about 0.01 wt. % of amorphous linaclotide.
- the present invention provides a composition comprising between about 50:50 and 99:1 ⁇ form linaclotide to amorphous linaclotide, such as, for example, between about 55:45 and 95:5 ⁇ form linaclotide to amorphous linaclotide, between about 60:40 and 90:10 ⁇ form linaclotide to amorphous linaclotide, between about 70:30 and 85:15 ⁇ form linaclotide to amorphous linaclotide, or even between about 75:25 and 99:1 ⁇ form linaclotide to amorphous linaclotide.
- a composition comprising between about 50:50 and 99:1 ⁇ form linaclotide to amorphous linaclotide, such as, for example, between about 55:45 and 95:5 ⁇ form linaclotide to amorphous linaclotide, between about 60:40 and 90:10 ⁇ form linaclotide to amorphous linaclotide,
- Formulations and preparations that comprise the ⁇ form linaclotide described herein can be prepared in any suitable manner, such as described, for example, in the Handbook of Pharmaceutical Excipients, American Pharmaceutical Association (current edition); Pharmaceutical Dosage Forms: Tablets (Lieberman, Lachman and Schwartz, editors) current edition, published by Marcel Dekker, Inc., as well as Remington's Pharmaceutical Sciences (Arthur Osol, editor), 1553-1593 (current edition).
- Administration of the present invention can be accomplished in any suitable manner according to patient needs, for example, orally, nasally, parenterally (e.g., subcutaneously, intravenously, intramuscularly, intrasternally, and/or by infusion), by inhalation, rectally, vaginally, topically, and/or by ocular administration.
- parenterally e.g., subcutaneously, intravenously, intramuscularly, intrasternally, and/or by infusion
- inhalation rectally, vaginally, topically, and/or by ocular administration.
- ⁇ form linaclotide can be administered alone or combined with various pharmaceutically acceptable carriers, diluents (such as sucrose, mannitol, lactose, starches) and excipients known in the art, including but not limited to suspending agents, solubilizers, buffering agents, binders, disintegrants, preservatives, colorants, flavorants, lubricants and the like.
- diluents such as sucrose, mannitol, lactose, starches
- excipients known in the art, including but not limited to suspending agents, solubilizers, buffering agents, binders, disintegrants, preservatives, colorants, flavorants, lubricants and the like.
- Time release capsules, tablets and gels are also advantageous in administering the compounds of the present invention.
- liquid oral dosage forms can also be used for administering ⁇ form linaclotide, including aqueous and non-aqueous solutions, emulsions, suspensions, syrups, and elixirs.
- dosage forms can also contain suitable inert diluents known in the art such as water and suitable excipients known in the art such as preservatives, wetting agents, sweeteners, flavorants, as well as agents for emulsifying and/or suspending the compounds of the invention.
- the ⁇ form linaclotide may be injected, for example, intravenously, in the form of an isotonic sterile solution.
- Suppositories for rectal administration of ⁇ form linaclotide can be prepared by mixing the compound with a suitable excipient such as cocoa butter, salicylates and polyethylene glycols.
- the pharmaceutical composition can be in the form of creams, ointments, liniments, lotions, emulsions, suspensions, gels, solutions, pastes, powders, sprays, and drops suitable for administration to the skin, eye, ear or nose. Topical administration may also involve transdermal administration via means such as transdermal patches.
- Aerosol formulations suitable for administering via inhalation also can be made.
- the compounds according to the invention can be administered by inhalation in the form of a powder (e.g., micronized) or in the form of atomized solutions or suspensions.
- the aerosol formulation can be placed into a pressurized acceptable propellant.
- the present invention provides methods of treating gastrointestinal disorders in a patient (e.g., mammal or human) diagnosed with one or more gastrointestinal disorders (such as, for example, irritable bowel syndrome, constipation-predominant irritable bowel syndrome, chronic constipation, opioid induced constipation and/or dyspepsia), wherein the method comprises administering an effective amount of ⁇ form linaclotide (or a composition comprising said ⁇ form linaclotide and optional additional components, additives, and/or species, as described herein) to said patient.
- a patient e.g., mammal or human
- gastrointestinal disorders such as, for example, irritable bowel syndrome, constipation-predominant irritable bowel syndrome, chronic constipation, opioid induced constipation and/or dyspepsia
- ⁇ form linaclotide or a composition comprising said ⁇ form linaclotide and optional additional components, additives, and/or species, as described herein
- the methods comprise administering a pharmaceutical composition comprising ⁇ form linaclotide and a pharmaceutically acceptable carriers and/or excipients.
- the methods comprise administering a pharmaceutical composition comprising ⁇ form linaclotide and a degradation product.
- the methods comprise administering a pharmaceutical composition comprising ⁇ form linaclotide and a hydrolysis product.
- the methods comprise administering a pharmaceutical composition comprising ⁇ form linaclotide and an acetylation product.
- the methods comprise administering a pharmaceutical composition comprising ⁇ form linaclotide and an oxidation product.
- the methods comprise administering a pharmaceutical composition comprising ⁇ form linaclotide and a formylation product.
- the methods comprise administering a pharmaceutical composition comprising ⁇ form linaclotide and a deamidation product.
- the methods comprise administering a pharmaceutical composition comprising ⁇ form linaclotide and a multimer product.
- the methods comprise administering a pharmaceutical composition comprising ⁇ form linaclotide and a dimer product.
- the methods comprise administering a pharmaceutical composition comprising ⁇ form linaclotide and an isomer product.
- ⁇ form linaclotide required to achieve desired results (such as desired treatment and/or symptom relief) of a subject is dependent on several understood factors, such as the identity and severity of the disorder being treated, as well as the age, weight, etc., of the patient being treated.
- a subject or patient in whom administration of the therapeutic compound is an effective therapeutic regimen for a disease or disorder is preferably a human, but can be any animal, including a laboratory animal in the context of a clinical trial or screening or activity experiment.
- the methods, compounds and compositions of the present invention are particularly suited to administration to any animal, particularly a mammal, and including, but by no means limited to, humans, domestic animals, such as feline or canine subjects, farm animals, such as but not limited to bovine, equine, caprine, ovine, and porcine subjects, wild animals (whether in the wild or in a zoological garden), research animals, such as mice, rats, rabbits, goats, sheep, pigs, dogs, cats, etc., avian species, such as chickens, turkeys, songbirds, etc., i.e., for veterinary medical use.
- the compounds of the present invention are administered as a mono-therapy. In other embodiments, the compounds of the present invention are administered as part of a combination therapy.
- a compound of the invention may be used in combination with other drugs or therapies that are used in the treatment/prevention/suppression and/or amelioration of the diseases or conditions for which compounds of the invention are useful.
- Such other drug(s) may be administered, by a route and in an amount commonly used therefore, contemporaneously or sequentially with a compound of the invention.
- a pharmaceutical unit dosage form containing such other drugs in addition to the compound of the invention may be employed.
- the pharmaceutical compositions of the present invention include those that also contain one or more other active ingredients, in addition to a compound of invention.
- FIG. 2 shows the X-ray diffraction pattern for the ⁇ crystalline form of linaclotide.
- linaclotide 100 mg was added to 10 ml aqueous acid solution (for example, 0.1N hydrochloric acid). The mixture was stirred using magnetic stirrer for 10-60 minutes at temperature in the range of 20° C. to 65° C. The suspension was carefully filtered into a glass container and the filtrate was stored under room temperature conditions. After a suitable formation period, the crystalline form of linaclotide was carefully isolated, washed, dried and analyzed using powder X-ray diffractometry.
- aqueous acid solution for example, 0.1N hydrochloric acid
- linaclotide 100 mg was added to 10 ml aqueous acid solution (for example, 0.1N hydrochloric acid). The mixture was stirred using magnetic stirrer for 10-60 minutes at temperature in the range of 20° C. to 65° C. The suspension was carefully filtered into a glass container and the filtrate was stored at 4° C. After a suitable formation period, the crystalline form of linaclotide was carefully isolated, washed, dried and analyzed using powder X-ray diffractometry.
- aqueous acid solution for example, 0.1N hydrochloric acid
- linaclotide 100 mg was added to 10 ml aqueous acid solution (for example, 0.1N hydrochloric acid). The mixture was stirred using magnetic stirrer for 10-60 minutes at temperature in the range of 20° C. to 65° C. The suspension was carefully filtered into a glass container. A weighed amount of a salt (for example sodium chloride) was added to the filtrate and it was stored under room temperature conditions. After a suitable formation period, the crystalline form of linaclotide was carefully isolated, washed, dried and analyzed using powder X-ray diffractometry.
- a salt for example sodium chloride
- linaclotide 100 mg was added to 10 ml aqueous acid solution (for example, 0.1N hydrochloric acid). The mixture was stirred using magnetic stirrer for 10-60 minutes at temperature in the range of 20° C. to 65° C. The suspension was carefully filtered into a glass container. A weighed amount of a salt (for example sodium chloride) was added to the filtrate and it was stored at 4° C. After a suitable formation period, the crystalline form of linaclotide was carefully isolated, washed, dried and analyzed using powder X-ray diffractometry.
- a salt for example sodium chloride
- linaclotide 100 mg was added to 10 ml aqueous acid solution (for example, 0.1N hydrochloric acid) containing a known amount of polymer (for example, polyvinyl pyrrolidone). The mixture was shaken using an end-over-end shaker for 6-48 hours at temperature in the range of 20° C. to 65° C. The suspension was carefully filtered into a glass container. A weighed amount of a salt (for example sodium chloride) was added to the filtrate and it was stored at 4° C. After a suitable formation period, the crystalline form of linaclotide was carefully isolated, washed, dried and analyzed using powder X-ray diffractometry.
- a salt for example sodium chloride
- the X-ray power diffraction patterns of the samples were determined in Example 1 using a wide-angle bench-top X-ray diffractometer (MiniFlex, Rigaku/MSC Inc., Woodlands, Tex.). The samples were loaded on zero background holders and exposed to CuK ⁇ radiation (30 kV ⁇ 15 mA). The instrument was operated in the step-scan mode, in increments of 0.05°2 ⁇ . The angular range was 5 to 40°2 ⁇ , and the scan rate was 0.1°2 ⁇ /min. The data collection and analyses were performed with commercially available software (JADE, version 7.1, Materials Data, Inc., Livermore, Calif.).
- the ⁇ -crystalline forms of linaclotide that were prepared in Examples 1A-1F were prepared and analyzed in this Example using a second wide-angle bench-top X-ray diffractometer (Model D8, Bruker AXS Inc., Madison Wis.). A small amount of the samples was loaded on a zero background holder and exposed to CuK ⁇ radiation (40 kV ⁇ 40 mA) in the wide-angle bench-top X-ray diffractometer (Model D8, Bruker AXS Inc., Madison Wis.). The instrument was operated in the step-scan mode, in increments of 0.05°2 ⁇ . The angular range was 5 to 30°2 ⁇ , and the scan rate ranged from 0.05-0.1°2 ⁇ /min. The data collection and analyses were performed with commercially available software (JADE, version 7.1, Materials Data, Inc., Livermore, Calif.).
- FIG. 3 shows the X-ray powder diffraction pattern for the crystalline form of linaclotide. Peak positions for the XRD are provided in Table 1.
- the ⁇ form linaclotide was also analyzed via Fourier Transform infrared spectroscopy by loading a small sample of the ⁇ form linaclotide (approx. 1 mg) onto a DurascopeTM diamond stage and exposing it to an IR beam in the FT-IR spectrometer using attenuated total diffuse reflectance (ATR) mode. All spectra were run at 4000-525 cm ⁇ 1 wavenumbers, 300 scans and 2 cm ⁇ 1 resolution. The Fourier Transform infrared spectrum for the ⁇ form linaclotide is shown in FIG. 4 .
- the ⁇ form linaclotide was also analyzed using a differential scanning calorimeter (MDSC Q1000, TA Instruments, New Castle, Del.) with a refrigerated cooling accessory.
- MDSC Q1000 TA Instruments, New Castle, Del.
- the instrument was calibrated with pure samples of indium. About 2-5 mg sample was weighed in open non-hermetic aluminum pans with a cover lid and heated under dry nitrogen purge (flow rate 50 ml/min) at 10° C./min. The data was analyzed using Universal Analysis 2000 (TA instruments, New Castle, Del.).
- the DSC thermogram of the ⁇ form linaclotide is shown in FIG. 5 .
- FIG. 6 shows the X-ray powder diffraction pattern for the crystalline form of linaclotide. Peak positions for the XRD are provided in Table 2.
- FIG. 7 shows the X-ray powder diffraction pattern for the crystalline form of linaclotide. Peak positions for the XRD are provided in Table 3.
- FIG. 8 shows the X-ray powder diffraction pattern for the crystalline form of linaclotide. Peak positions for the XRD are provided in Table 4.
- FIG. 9 shows the X-ray powder diffraction pattern for the crystalline form of linaclotide. Peak positions for the XRD are provided in Table 5.
- linaclotide 100 mg was mixed with 0.1N hydrochloric acid containing a known amount of polymer (for example, polyvinyl pyrrolidone). The mixture was shaken using an end-over-end shaker for 6-48 hours at temperature in the range of 20° C. to 65° C. The suspension was carefully filtered into a glass container. A weighed amount of sodium chloride was added to the filtrate and it was stored at 4° C. After a suitable formation period, the ⁇ crystalline form of linaclotide was carefully isolated, washed, dried and analyzed using powder X-ray diffractometry.
- FIG. 10 shows the X-ray powder diffraction pattern for the crystalline form of linaclotide. Peak positions for the XRD are provided in Table 6.
- FIG. 11 shows the X-ray powder diffraction pattern for the crystalline form of linaclotide. Peak positions for the XRD are provided in Table 7.
- FIG. 12 shows the X-ray powder diffraction pattern for the crystalline form of linaclotide. Peak positions for the XRD are provided in Table 8.
- FIG. 13 shows the X-ray powder diffraction pattern for the crystalline form of linaclotide. Peak positions for the XRD are provided in Table 9.
- the relative chemical purity and stability of amorphous and crystalline linaclotide was studied using reverse phase high performance liquid chromatography (HPLC).
- HPLC reverse phase high performance liquid chromatography
- the chemical identification was conducted using reverse phase high performance liquid chromatography coupled with mass spectroscopy (HPLC-MS).
- HPLC-MS mass spectroscopy
- the mass spectroscopic analysis was performed at Enhance MS scan (EMS) mode with positive ionization and a scan range (m/z) of 600-1600.
- a Perkin Elmer series 200 LC instrument (Perkin Elmer, Waltham, Mass.) was used with a YMC Pro C18 column (150 mm ⁇ 3.0 mm, 3 ⁇ m) (Waters Corporation, Milford, Mass.). The column temperature was set at 40° C. while the auto sampler temperature was maintained at 4° C. using a peltier tray. The injection volume was 50 ⁇ l.
- a gradient (0.6 ml/minute) run was used comprising of two solvents; A (97.9% Water, 2% Acetonitrile, 0.1% Trifluoroacetic Acid) and B (94.9% Acetonitrile, 5% Water, 0.1% Trifluoroacetic Acid). The gradient was set according to the scheme described in Table 10. The effluent was detected at 220 nm using a UV detector.
- a Perkin Elmer Series 200 LC-MS instrument (Perkin Elmer, Waltham, Mass.) was used with a Pursuit XR C18 column (150 ⁇ 2 mm, 3 ⁇ m). The column temperature was set at 40° C. while the autosampler temperature was maintained at 4° C. using a peltier tray. The injection volume was 5 ⁇ l. A gradient (0.25 ml/minute) run was used comprising of two solvents; A (0.1% trifluoroacetic acid in water) and B (0.1% trifluoroacetic acid in acetonitrile). The gradient was set according to the scheme described in Table 11. The effluent was detected at 220 nm using a UV detector. The mass spectroscopic analysis was performed at Enhance MS scan (EMS) mode with positive ionization and a scan range (m/z) of 600-1600.
- EMS Enhance MS scan
- the precipitates prepared in Examples 1A and 2A were chemically identified as linaclotide based on HPLC-MS analysis. The purity of the precipitate was found to be in the range of 95% to 100%,
- the remaining 19.2% and 4.1% of the amorphous and ⁇ -form linaclotide respectively may comprise multimers.
- the ⁇ -crystalline form of linaclotide was found to have a substantially better stability profile than amorphous linaclotide, under the study conditions. Additionally, as is illustrated, the ⁇ -crystalline form of linaclotide had a significantly lower concentration of degradation products, as well as significantly less multimer formation.
- the ⁇ -crystalline form of linaclotide was also found to have lower concentrations of degradation products (water mediated de-amidation and hydrolysis) and non-disulfide linked multimers as compared to amorphous linaclotide after storage for three months in induction sealed 45 cc high-density polyethylene bottles at 40° C./75% RH.
- acid-induced hydrolysis was pronounced in the crystalline form.
- a linaclotide hydrolysis product was prepared by transforming Asn in the 7 position to Asp (the numbering of linaclotide starts with 1 at the N-terminal Cys).
- the linaclotide hydrolysis product was synthesized using a solid phase peptide synthesis technique. The structure of the linaclotide hydrolysis product is shown below:
- the linaclotide hydrolysis product may also be prepared by other methods known in the art, e.g., by isolation from linaclotide preparations using chromatographic techniques or by recombinant expression of a nucleic acid encoding the linaclotide hydrolysis product (CCEYCCDPACTGCY), optionally followed by oxidation of the cysteine residues to form the disulfide linkages.
- CCEYCCDPACTGCY a nucleic acid encoding the linaclotide hydrolysis product
- the crystalline forms of linaclotide have physical properties (e.g., stability properties) that are surprising and unexpected as compared to amorphous linaclotide and/or other crystalline forms of linaclotide.
- the crystalline forms of linaclotide may also have synergy with other active or inactive components resulting in enhanced performance characteristics or properties of pharmaceutical compositions comprising one or more crystalline forms of the present invention.
Abstract
The present invention relates to crystalline forms of linaclotide, as well as to various methods and processes for the preparation and use of the crystalline forms.
Description
- This application claims the benefit of U.S. Provisional Application No. 61/116,156, filed Nov. 19, 2008, the entire contents of which are hereby incorporated by reference.
- The present invention relates to a novel α-crystalline form of linaclotide, as well as processes for the preparation of the α-crystalline form, compositions comprising the α-crystalline form, and methods of using the α-crystalline form.
- U.S. Pat. No. 7,304,036 discloses peptides that act as agonists of the guanylate cyclase C (GC—C) receptor for the treatment of gastrointestinal disorders. One particular peptide disclosed therein is linaclotide, which consists of the following amino acid sequence: Cys Cys Glu Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr.
- U.S. Pat. Nos. 7,304,036 and 7,371,727 disclose methods for the preparation of linaclotide and related peptides. The contents of U.S. Pat. Nos. 7,304,036 and 7,371,727 are incorporated herein by reference, in their entirety.
- There remains a need in the art for improved forms of linaclotide having improved properties.
- The present invention relates to a new crystalline form or polymorph of linaclotide, which has surprisingly and unexpectedly enhanced properties, such as enhanced or greater stability, as compared to amorphous linaclotide. In addition, such a crystalline form of linaclotide may have enhanced storage stability and enhanced stability against chemical degradation as compared to amorphous linaclotide.
- The present invention relates to a novel α-crystalline form of linaclotide. Various methods and processes for the preparation and use of the crystalline form are also described herein.
-
FIG. 1 shows the X-ray powder diffraction pattern of amorphous linaclotide. -
FIG. 2 shows the X-ray powder diffraction pattern of an α-crystalline form of linaclotide. -
FIG. 3 shows the X-ray powder diffraction pattern of an α-crystalline form of linaclotide. -
FIG. 4 shows the Fourier Transform infrared spectrum of an α-crystalline form of linaclotide. -
FIG. 5 shows a differential scanning calorimetry (DSC) thermogram of an α-crystalline form of linaclotide. -
FIG. 6 shows the X-ray powder diffraction pattern of an α-crystalline form of linaclotide. -
FIG. 7 shows the X-ray powder diffraction pattern of an α-crystalline form of linaclotide. -
FIG. 8 shows the X-ray powder diffraction pattern of an α-crystalline form of linaclotide. -
FIG. 9 shows the X-ray powder diffraction pattern of an α-crystalline form of linaclotide. -
FIG. 10 shows the X-ray powder diffraction pattern of an α-crystalline form of linaclotide. -
FIG. 11 shows the X-ray powder diffraction pattern of an α-crystalline form of linaclotide. -
FIG. 12 shows the X-ray powder diffraction pattern of an α-crystalline form of linaclotide. -
FIG. 13 shows the X-ray powder diffraction pattern of an α-crystalline form of linaclotide. - The present invention provides crystalline forms of linaclotide. The methods for preparation as disclosed in U.S. Pat. Nos. 7,304,036 and 7,371,727 yield linaclotide in an amorphous state. The X-ray powder diffraction pattern of amorphous linaclotide is illustrated in
FIG. 1 . - In one aspect, the present invention relates to crystalline forms of linaclotide, specifically α-crystalline forms of linaclotide (α form linaclotide).
- In some embodiments, the α form linaclotide is characterized by an X-ray powder diffraction pattern comprising a peak at about 6.2+/−0.5 degrees 2θ.
- In some embodiments, the α form linaclotide is characterized by an X-ray powder diffraction pattern comprising a peak at about 7.8+/−0.5 degrees 2θ.
- In some embodiments, the α form linaclotide is characterized by an X-ray powder diffraction pattern comprising a peak at about 8.6+/−0.5 degrees 2θ.
- In certain embodiments, the α form linaclotide is characterized by an X-ray powder diffraction pattern comprising a peak at about 9.7+/−0.5 degrees 2θ.
- In certain embodiments, the α form linaclotide is characterized by an X-ray powder diffraction pattern comprising a peak at about 10.3+/−0.5 degrees 2θ.
- In certain embodiments, the α form linaclotide is characterized by an X-ray powder diffraction pattern comprising a peak at about 11.4+/−0.5 degrees 2θ.
- In certain embodiments, the α form linaclotide is characterized by an X-ray powder diffraction pattern comprising a peak at about 14.3+/−0.5 degrees 2θ.
- In certain embodiments, the α form linaclotide is characterized by an X-ray powder diffraction pattern comprising a peak at about 16.0+/−0.5 degrees 2θ.
- In certain embodiments, the α form linaclotide is characterized by an X-ray powder diffraction pattern comprising a peak at about 17.9+/−0.5 degrees 2θ.
- In certain embodiments, the α form linaclotide is characterized by an X-ray powder diffraction pattern comprising a peak at about 19.5+/−0.5 degrees 2θ.
- In certain embodiments, the α form linaclotide is characterized by an X-ray powder diffraction pattern comprising a peak at about 20.9+/−0.5 degrees 2θ.
- In certain embodiments, the α form linaclotide is characterized by an X-ray powder diffraction pattern comprising a peak at about 21.6+/−0.5 degrees 2θ.
- In certain embodiments, the α form linaclotide is characterized by an X-ray powder diffraction pattern comprising a peak at about 22.6+/−0.5 degrees 2θ.
- In certain embodiments, the α form linaclotide is characterized by an X-ray powder diffraction pattern comprising a peak at about 23.9+/−0.5 degrees 2θ.
- In certain embodiments, the α form linaclotide is characterized by an X-ray powder diffraction pattern comprising a peak at about 24.4+/−0.5 degrees 2θ.
- In certain embodiments, the α form linaclotide is characterized by an X-ray powder diffraction pattern comprising a peak at about 25.2+/−0.5 degrees 2θ.
- In exemplary embodiments, the α form linaclotide is characterized by an X-ray powder diffraction pattern comprising peaks at about 6.2, about 7.8, about 11.4, about 16.0, about 19.5, and at about 23.9+/−0.5 degrees 2θ.
- In exemplary embodiments, the α form linaclotide is characterized by an X-ray powder diffraction pattern comprising peaks at about 6.2, about 7.8, about 8.6, about 9.7, about 10.3, about 11.4, about 14.3, about 16.0, about 17.9, about 19.5, about 20.9, about 21.6, about 22.6, about 23.9, about 24.4, and at about 25.2+/−0.5 degrees 2θ.
- In exemplary embodiments, the α form linaclotide is characterized by an X-ray powder diffraction pattern comprising peaks at about 6.2 and at about 7.8+/−0.5 degrees 2θ. In exemplary embodiments, the α form linaclotide is characterized by an X-ray powder diffraction pattern comprising peaks at about 7.8 and at about 23.9+/−0.5 degrees 2θ. In exemplary embodiments, the α form linaclotide is characterized by an X-ray powder diffraction pattern comprising peaks at about 6.2, about 7.8 and about 23.9 +/−0.5 degrees 2θ.
- In exemplary embodiments, the α form linaclotide is characterized by an X-ray powder diffraction pattern comprising peaks at about 6.2, about 7.8, about 19.5 and about 23.9+/−0.5 degrees 2θ. In exemplary embodiments, the α form linaclotide is characterized by an X-ray powder diffraction pattern comprising peaks at about 6.2, about 7.8, about 22.6 and about 23.9+/−0.5 degrees 2θ.
- In exemplary embodiments, the α form linaclotide is characterized by an X-ray powder diffraction pattern comprising peaks at about 6.2, about 7.8, about 23.9+/−0.5 degrees 2θ and optionally one or more peaks at about 19.5+/−0.5 degrees 2θ and/or about 22.6+/−0.5 degrees 2θ.
- In exemplary embodiments, the α form linaclotide is characterized by an X-ray powder diffraction pattern comprising peaks at about 6.2, about 7.8, about 19.5, about 22.6 and about 23.9+/−0.5 degrees 2θ.
- In exemplary embodiments, the α form linaclotide is characterized by an X-ray powder diffraction pattern substantially as shown in
FIG. 2 orFIG. 3 . - In some embodiments, the α form linaclotide is characterized by an X-ray powder diffraction pattern comprising one or more peaks as provided in Table 1. In some embodiments, the α form linaclotide is characterized by an X-ray powder diffraction pattern comprising one or more peaks at about 5.7, about 7.7, about 23.8+/−0.5 degrees 2θ and optionally one or more peaks at about 7.0, about 8.5, about 9.6, about 10.2, about 11.3, about 12.6, about 13.7, about 14.3, about 15.5, about 16.4, about 17.1, about 17.9, about 18.5, about 19.4, about 20.8, about 21.5, about 22.5, about 23.1, about 24.5, about 25.5, about 26.1, about 27.5, about 28.2, about 28.8 and/or about 29.6+/−0.5 degrees 2θ. As used herein, unless otherwise indicated, the phrase “one or more peaks” should be understood to be inclusive of (i) crystalline forms that have XRD peaks at every peak value recited after this phrase, (ii) crystalline forms that have an XRD peak at only one of the peak values recited after this phrase, as well (iii) crystalline forms that have XRD peaks at two or more (e.g., three or more, four or more, five or more, six or more, or even seven or more) of the peak values recited after this phrase.
- In some embodiments, the α form linaclotide is characterized by an X-ray powder diffraction pattern comprising peaks at about 5.7 and about 7.7+/−0.5 degrees 2θ. In some embodiments, the α form linaclotide is characterized by an X-ray powder diffraction pattern comprising peaks at about 5.7, about 7.7 and about 23.8+/−0.5 degrees 2θ.
- In some embodiments, the α form linaclotide is characterized by an X-ray powder diffraction pattern comprising peaks at about 5.7, about 7.7, about 23.8+/−0.5 degrees 2θ and optionally one or more peaks at about 19.4+/−0.5 degrees 2θ and/or at about 22.5+/−0.5 degrees 2θ.
- In some embodiments, the α form linaclotide is characterized by an X-ray powder diffraction pattern comprising peaks at about 5.7, about 7.7, about 19.4 and about 23.8+/−0.5 degrees 2θ.
- In some embodiments, the α form linaclotide is characterized by an X-ray powder diffraction pattern comprising peaks at about 5.7, about 7.7, about 22.5 and about 23.8+/−0.5 degrees 2θ. In some embodiments, the α form linaclotide is characterized by an X-ray powder diffraction pattern comprising peaks at about 5.7, about 7.7, about 19.4, about 22.5 and about 23.8+/−0.5 degrees 2θ.
- In some embodiments, the α form linaclotide is characterized by an X-ray powder diffraction pattern substantially as shown in
FIG. 6 . In some embodiments, the α form linaclotide is characterized by an X-ray powder diffraction pattern comprising one or more peaks as provided in Table 2. In some embodiments, a crystalline form of linaclotide is provided, wherein the crystalline form has an X-ray powder diffraction pattern comprising peaks at about 5.7, about 7.7 and about 23.8+/−0.5 degrees 2θ and optionally one or more peaks at about 6.3, about 8.4, about 9.5, about 10.5, about 11.7, about 12.4, about 13.6, about 14.7, about 15.4, about 17.0, about 17.8, about 19.6, about 20.6, about 21.3, about 22.5, about 24.4, about 25.1, about 26.5, about 27.1, about 27.7, and/or about 28.7+/−0.5 degrees 2θ. - In some embodiments, the α form linaclotide is characterized by an X-ray powder diffraction pattern substantially as shown in
FIG. 7 . In some embodiments, a crystalline form of linaclotide is provided, wherein the crystalline form has an X-ray powder diffraction pattern comprising one or more peaks as provided in Table 3. In some embodiments, a crystalline form of linaclotide is provided, wherein the crystalline form has an X-ray powder diffraction pattern comprising peaks at about 5.8, about 7.7 and about 23.9+/−0.5 degrees 2θ and optionally one or more peaks at about 6.4, about 8.4, about 9.4, about 10.5, about 11.5, about 12.9, about 13.6, about 14.9, about 15.9, about 17.4, about 18.2, about 18.8, about 19.4, about 20.4, about 22.5, about 23.3 and/or about 25.7+/−0.5 degrees 2θ. - In some embodiments, the α form linaclotide is characterized by an X-ray powder diffraction pattern substantially as shown in
FIG. 8 . In some embodiments, a crystalline form of linaclotide is provided, wherein the crystalline form has an X-ray powder diffraction pattern comprising one or more peaks as provided in Table 4. In some embodiments, a crystalline form of linaclotide is provided, wherein the crystalline form has an X-ray powder diffraction pattern comprising one or more peaks at about 5.6, about 7.7, about 23.8 and optionally one or more peaks at about 8.4, about 9.5, about 10.1, about 11.0, about 11.8, about 12.2, about 14.1, about 14.9, about 15.4, about 16.3, about 17.0, about 17.8, about 18.7, about 19.4, about 20.7, about 21.5, about 22.5, about 24.4 and/or about 25.4+/−0.5 degrees 2θ. - In some embodiments, the α form linaclotide is characterized by an X-ray powder diffraction pattern substantially as shown in
FIG. 9 . In some embodiments, a crystalline form of linaclotide is provided, wherein the crystalline form has an X-ray powder diffraction pattern comprising one or more peaks as provided in Table 5. In some embodiments, a crystalline form of linaclotide is provided, wherein the crystalline form has an X-ray powder diffraction pattern comprising peaks at about 7.7, about 23.8+/−0.5 degrees 2θ and optionally one or more peaks at about 5.6, about 9.5, about 10.1, about 11.0, about 11.8, about 12.5, about 14.1, about 14.9, about 15.9, about 17.0, about 17.8, about 19.4, about 20.2, about 20.7, about 21.1, about 21.5, about 22.5, about 23.1, about 24.4, about 25.4, and/or about 27.1+/−0.5 degrees 2θ. - In some embodiments, the α form linaclotide is characterized by an X-ray powder diffraction pattern substantially as shown in
FIG. 10 . In some embodiments, a crystalline form of linaclotide is provided, wherein the crystalline form has an X-ray powder diffraction pattern comprising one or more peaks as provided in Table 6. In some embodiments, a crystalline form of linaclotide is provided, wherein the crystalline form has an X-ray powder diffraction pattern comprising peaks at about 5.6 and about 7.7+/−0.5 degrees 2θ and optionally one or more peaks at about 8.5, about 10.2, about 11.2, about 12.3, about 13.7, about 16.0, about 17.9, about 19.5, about 20.4, about 22.5, about 23.8 about 25.5, about 27.3, and/or about 27.6+/−0.5 degrees 2θ. - In some embodiments, the α form linaclotide is characterized by an X-ray powder diffraction pattern substantially as shown in
FIG. 11 . In some embodiments, a crystalline form of linaclotide is provided, wherein the crystalline form has an X-ray powder diffraction pattern comprising one or more peaks as provided in Table 7. In some embodiments, a crystalline form of linaclotide is provided, wherein the crystalline form has an X-ray powder diffraction pattern comprising one or more peaks at about 5.6, about 6.0, about 6.3, about 7.7, about 8.1, about 8.4, about 9.5, about 10.1, about 11.0, about 11.2, about 11.8, about 12.2, about 12.5, about 13.6, about 14.2, about 14.9, about 15.4, about 15.9, about 16.3, about 17.0, about 17.8, about 18.9, about 19.4, about 20.2, about 20.7, about 21.4, about 22.4, about 23.8, about 24.4 and/or about 25.4+/−0.5 degrees 2θ. - In some embodiments, the α form linaclotide is characterized by an X-ray powder diffraction pattern substantially as shown in
FIG. 12 . In some embodiments, a crystalline form of linaclotide is provided, wherein the crystalline form has an X-ray powder diffraction pattern comprising one or more peaks as provided in Table 8. In some embodiments, a crystalline form of linaclotide is provided, wherein the crystalline form has an X-ray powder diffraction pattern comprising one or more peaks at about 5.6, about 6.3, about 7.7, about 8.5, about 9.5, about 10.6, about 11.2, about 12.1, about 13.6, about 14.6, about 15.4, about 16.3, about 17.0, about 17.8, about 19.3, about 20.7, about 21.5, about 22.5, about 23.1, about 23.7 and/or about 25.3+/−0.5 degrees 2θ. - In some embodiments, the α form linaclotide is characterized by an X-ray powder diffraction pattern substantially as shown in
FIG. 13 . In some embodiments, a crystalline form of linaclotide is provided, wherein the crystalline form has an X-ray powder diffraction pattern comprising one or more peaks as provided in Table 9. In some embodiments, a crystalline form of linaclotide is provided, wherein the crystalline form has an X-ray powder diffraction pattern comprising one or more peaks at about 5.6, about 7.0, about 7.7, about 8.4, about 9.5, about 10.1, about 11.2, about 12.4, about 13.6, about 14.6, about 15.8, about 16.6, about 18.0, about 18.9, about 19.7, about 20.7, about 21.4, about 22.4, about 23.0, about 24.1 and/or about 25.0+/−0.5 degrees 2θ. - In some embodiments, α form linaclotide is characterized by an X-ray powder diffraction pattern comprising peaks having d-spacing values at about 3.7, about 11.5, and about 15.5+/−0.5 angstroms (Å). In some embodiments, α form linaclotide is characterized by an X-ray powder diffraction pattern comprising peaks having d-spacing values at about 3.7, about 4.5, about 11.5, and about 15.5+/−0.5 angstroms (Å).
- In some embodiments, the X-ray powder diffraction peaks recited herein for particular embodiments can vary by ±0.4 degrees 2θ, by ±0.3 degrees 2θ, by ±0.2 degrees 2θ, or even by ±0.1 degrees 2θ. In some embodiments, for example, a crystalline form of linaclotide is provided having an X-ray power diffraction pattern comprising peaks at about 5.7, about 7.7 and about 23.8+/−0.3 degrees 2θ.
- In some embodiments, α form linaclotide is characterized by an X-ray powder diffraction pattern comprising peaks having d-spacing values at about 1.4, about 1.1, about 1.0, about 0.9, about 0.8, about 0.6, about 0.5 and about 0.4+/−3% nm.
- In some embodiments, the α form linaclotide is characterized by an X-ray powder diffraction pattern comprising d-spacing values at about 1.4, about 1.1, about 0.8, about 0.6, about 0.5 and about 0.4+/−3% nm.
- In exemplary embodiments, the α form linaclotide is characterized by an X-ray powder diffraction pattern comprising a d-spacing value at about 1.4+/−3% nm.
- In exemplary embodiments, the α form linaclotide is characterized by an X-ray powder diffraction pattern comprising a d-spacing value at about 1.1+/−3% nm.
- In exemplary embodiments, the α form linaclotide is characterized by an X-ray powder diffraction pattern comprising a d-spacing value at about 1.0+/−3% nm.
- In exemplary embodiments, the α form linaclotide is characterized by an X-ray powder diffraction pattern comprising a d-spacing value at about 0.9+/−3% nm.
- In exemplary embodiments, the α form linaclotide is characterized by an X-ray powder diffraction pattern comprising a d-spacing value at about 0.8+/−3% nm.
- In exemplary embodiments, the α form linaclotide is characterized by an X-ray powder diffraction pattern comprising a d-spacing value at about 0.6+/−3% nm.
- In exemplary embodiments, the α form linaclotide is characterized by an X-ray powder diffraction pattern comprising a d-spacing value at about 0.5+/−3% nm.
- In exemplary embodiments, the α form linaclotide is characterized by an X-ray powder diffraction pattern comprising a d-spacing value at about 0.4+/−3% nm.
- In some embodiments, the α form linaclotide is characterized by a Fourier Transform infrared spectrum substantially as shown in
FIG. 4 . - In some embodiments, the α form linaclotide is characterized by a DSC thermogram substantially as shown in
FIG. 5 . - In another aspect, the present invention provides processes for preparing the α-crystalline forms of linaclotide described herein. In some embodiments, methods for manufacturing a medicament comprising α form linaclotide that are useful in the treatment of a gastrointestinal disorder are provided. In some embodiments, for example, α form linaclotide is produced by crystallizing linaclotide to form α form linaclotide and optionally isolating the α form linaclotide. In some embodiments, α form linaclotide is prepared by crystallizing linaclotide in an aqueous acid solution and optionally isolating the α-crystalline form of linaclotide. Any suitable aqueous acid solution can be used in this regard, such as, for example, any solution of acid in water at various strengths or concentrations. Such acids may include, but are not limited to, hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, methane sulfonic acid, phosphoric acid, acetic acid, lactic acid, p-toluene sulfonic acid, oxalic acid, glutamic acid, fumaric acid, malic acid, aspartic acid, ascorbic acid, benzoic acid, maleic acid and succinic acid. In some embodiments, the aqueous acid solution is selected from hydrochloric acid, hydrobromic acid, nitric acid, methane sulfonic acid, acetic acid, lactic acid, p-toluene sulfonic acid, oxalic acid, glutamic acid, aspartic acid, ascorbic acid, benzoic acid and succinic acid.
- The α-crystalline form of linaclotide can be identified, distinguished, and separated from amorphous linaclotide in any suitable manner, such as on the basis of differences in the diffraction, thermal and/or spectroscopic properties of these different forms of linaclotide. Suitable such methods include, for example, X-ray powder diffractometry, capillary melting point determination, thermogravimetric analysis (TGA), differential scanning calorimetry (DSC) and/or spectroscopic methodologies (such as Raman spectroscopy and/or infrared (IR) spectroscopy).
- One skilled in the art will understand that the relative intensities and positions of the peaks obtained by X-ray powder diffraction may vary depending upon, inter alia, the sample preparation technique, the sample mounting procedure, and the particular instrument employed. For example, in additional embodiments, the listed X-ray powder diffraction pattern peaks for the crystalline form of linaclotide is about +/−0.2 degrees 2θ.
- The α form linaclotide can have any desired degree of purity, relative to other substances or components in the preparation. In one embodiment, the present invention provides an α-crystalline form of linaclotide that is substantially pure, such as, for example, having greater than 40%, greater than 50%, greater than 60%, greater than 70%, greater than 80%, greater than 85%, greater than 90%, greater than 95%, greater than 96%, greater than 97%, greater than 98%, greater than 99%, greater than 99.2%, greater than 99.4%, greater than 99.6%, greater than 99.6%, or even greater than 99.9% purity, relative to other substances or components in the preparation.
- In exemplary embodiments, the α form linaclotide is about 45% to 95% pure, such as, for example, about 50% to 95% pure, about 55% to 90% pure, about 60% to 95% pure, or even about 70% to 99% pure, relative to other substances or components in the preparation. In some embodiments, the α form linaclotide is about 95% to 99% pure. In some embodiments, the α form linaclotide is about 90% to 95% pure. In some embodiments, the α form linaclotide is about 85% to 90% pure. In some embodiments, the α form linaclotide is about 80% to 85% pure. In some embodiments, the α form linaclotide is about 75% to 80% pure. In some embodiments, the α form linaclotide is about 70% to 75% pure. In certain embodiments, the α form linaclotide is about 65% to 70% pure. In some embodiments, the α form linaclotide is about 60% to 65% pure. In other embodiments, the α form linaclotide is about 55% to 60% pure. In yet other embodiments, the α form linaclotide is about 50% to 55% pure. In some embodiments, the α form linaclotide is about 45% to 50% pure.
- Compositions
- In some embodiments, the present invention provides a composition, formulation, or dosage form that comprises α form linaclotide and optional additional components, additives and/or species, such as, for example one or more ion species that interact with linaclotide.
- Such additional components, additives, and/or species can be administered alone or as an active ingredient of the composition, formulation, or dosage form. Moreover, the additional components, additives, and/or species can be administered before, after, and/or concurrently with α form linaclotide.
- In some embodiments, the additional components, additives, and/or species are administered separately to a patient or subject (e.g., in a separate formulation or dosage form) from the α form linaclotide.
- In some embodiments, the optional additional components, additives, and/or species comprise an active component of the formulation.
- In some embodiments, the optional components comprise one or more pharmaceutically-acceptable carriers and/or excipients.
- In one aspect, the present invention provides a composition comprising α form linaclotide and a degradation product, such as a hydrolysis product, acetylation product, a formylation product, an oxidation product, a water-mediated degradation product, and/or a deamidation product.
- The composition can contain any desired purity relative to hydrolysis product(s). In exemplary embodiments, the composition comprises less than about 10% by weight of hydrolysis product(s), relative to the total weight of the composition, such as, for example, less than about 7.5 wt. %, less than about 5 wt. %, or even less than about 2 wt. % of hydrolysis product(s). In some embodiments, the composition comprises from about 0.05% to about 5% by weight of hydrolysis product(s). In certain embodiments, the composition comprises from about 0.05% to about 2% by weight of the hydrolysis product(s). In certain embodiments, the composition may comprise from about 0.1% to about 2% by weight of the hydrolysis product(s).
- Alternatively, or in addition, the composition can contain any desired purity relative to acetylation product(s). In exemplary embodiments, the acetylation product may comprise less than 10% by weight of the composition. In exemplary embodiments, the acetylation product may comprise less than 7.5% by weight of the composition. In exemplary embodiments, the acetylation product may comprise less than 5% by weight of the composition. In some embodiments, the acetylation product may comprise less than 2% by weight of the composition. In other embodiments, the acetylation product may comprise less than 1% by weight of the composition. In still other embodiments, the acetylation product may comprise less than 0.5% by weight of the composition. In some embodiments, the acetylation product may comprise from about 0.05% to about 5% by weight of the composition. In some embodiments, the acetylation product may comprise from about 0.05% to about 2% by weight of the composition. In other embodiments, the acetylation product may comprise from about 0.1% to about 2% by weight of the composition. In yet other embodiments, the acetylation product may comprise from about 0.1% to about 2% by weight of the composition.
- Alternatively, or in addition, the composition can contain any desired purity relative to formylation product(s). In exemplary embodiments, the formylation product may comprise less than 10% by weight of the composition. In exemplary embodiments, the formylation product may comprise less than 7.5% by weight of the composition. In exemplary embodiments, the formylation product may comprise less than 5% by weight of the composition. In some embodiments, the formylation product may comprise less than 2% by weight of the composition. In other embodiments, the formylation product may comprise from about 0.05% to about 5% by weight of the composition. In some embodiments, the formylation product may comprise from about 0.05% to about 2% by weight of the composition. In other embodiments, the formylation product may comprise from about 0.1% to about 2% by weight of the composition.
- Alternatively, or in addition, the composition can contain any desired purity relative to oxidation product(s). In some embodiments, the oxidation product may comprise less than 10% by weight of the composition. In some embodiments, the oxidation product may comprise less than 7.5% by weight of the composition. In some embodiments, the oxidation product may comprise less than 5% by weight of the composition. In other embodiments, the oxidation product may comprise less than 2% by weight of the composition. In still other embodiments, the oxidation product may comprise from about 0.05% to about 5% by weight of the composition. In exemplary embodiments, the oxidation product may comprise from about 0.05% to about 2% by weight of the composition. In yet other embodiments, the oxidation product may comprise from about 0.1% to about 2% by weight of the composition.
- Alternatively, or in addition, the composition can contain any desired purity relative to water-mediated degradation product(s). In some embodiments, the water-mediated degradation product(s) may comprise less than 10% by weight of the composition. In some embodiments, the water-mediated degradation product(s) may comprise less than 7.5% by weight of the composition. In some embodiments, the water-mediated degradation product(s) may comprise less than 5% by weight of the composition. In other embodiments, the water-mediated degradation product(s) may comprise less than 2% by weight of the composition. In still other embodiments, the water-mediated degradation product(s) may comprise from about 0.05% to about 5% by weight of the composition. In exemplary embodiments, the water-mediated degradation product(s) may comprise from about 0.05% to about 2% by weight of the composition. In yet other embodiments, the water-mediated degradation product(s) may comprise from about 0.1% to about 2% by weight of the composition.
- Alternatively, or in addition, the composition can contain any desired purity relative to deamidation product(s). In some embodiments, the deamidation product may comprise less than 10% by weight of the composition. In some embodiments, the deamidation product may comprise less than 7.5% by weight of the composition. In some embodiments, the deamidation product may comprise less than 5% by weight of the composition. In other embodiments, the deamidation product may comprise less than 2% by weight of the composition. In still other embodiments, the deamidation product may comprise from about 0.05% to about 5% by weight of the composition. In exemplary embodiments, the deamidation product may comprise from about 0.05% to about 2% by weight of the composition. In yet other embodiments, the deamidation product may comprise from about 0.1% to about 2% by weight of the composition.
- In another aspect, the invention provides a composition comprising α form linaclotide and less than 10 wt. % (such as less than 8 wt. %, less than 6 wt. %, less than 5 wt. %, less than 4 wt. %, less than 3 wt. %, less than 2 wt. %, less than 1 wt. %, less than 0.5 wt. %, or even less than 0.25 wt. %) of a combined total of a degradation product, such as a hydrolysis product, a formylation product, an oxidation product, a water-mediated degradation product, and/or a deamidation product.
- In another aspect, the invention provides a composition comprising α form linaclotide and less than 20 wt. % (such as less than 18 wt. %, less than 16 wt. %, less than 14 wt. %, less than 12 wt. %, less than 10 wt. %, less than 8 wt. %, less than 6 wt. %, less than 5 wt. %, less than 4 wt. %, less than 3 wt. %, less than 2 wt. %, less than 1 wt. %, less than 0.5 wt. %, or even less than 0.25 wt. %) of a combined total of a degradation product, such as a hydrolysis product, an acetylation product, a formylation product, an oxidation product, a water-mediated degradation product, and/or a deamidation product.
- In one aspect, the present invention provides a composition comprising α form linaclotide and multimers. In some embodiments, the multimers may be formed due to disulfide linkages. In some embodiments, the multimers may be formed due to non-disulfide linkages. In some embodiments, the composition may contain any desired purity relative to multimers. In some embodiments, the composition comprises less than about 20 wt. % of multimers, such as, for example, less than about 18 wt. %, less than about 16 wt. %, less than about 14 wt. %, less than about 12 wt. %, less than about 10 wt. %, less than about 8 wt. %, less than about 6 wt. %, less than about 5 wt. %, less than about 4 wt. %, less than about 3 wt. %, less than about 2 wt. %, less than about 1 wt. %, less than about 0.5 wt. %, or even less than about 0.1 wt. % of multimers.
- In some embodiments, the compositions may comprise α form linaclotide and a dimer. In some embodiments, the composition comprises less than about 20 wt. % of dimers, such as, for example, less than about 18 wt. %, less than about 16 wt. %, less than about 14 wt. %, less than about 12 wt. %, less than about 10 wt. %, less than about 8 wt. %, less than about 6 wt. %, less than about 5 wt. %, less than about 4 wt. %, less than about 3 wt. %, less than about 2 wt. %, less than about 1 wt. %, less than about 0.5 wt. %, or even less than about 0.1 wt. % of dimers.
- In another aspect, the present invention provides a composition comprising α form linaclotide and an isomer. In some embodiments, the composition comprises less than about 20 wt. % of isomers, such as, for example, less than about 18 wt. %, less than about 16 wt. %, less than about 14 wt. %, less than about 12 wt. %, less than about 10 wt. %, less than about 8 wt. %, less than about 6 wt. %, less than about 5 wt. %, less than about 4 wt. %, less than about 3 wt. %, less than about 2 wt. %, less than about 1 wt. %, less than about 0.5 wt. %, or even less than about 0.1 wt. % of isomers.
- In one aspect, the present invention provides a composition comprising α form linaclotide and less than about 40 wt %, such as less than about 30 wt. %, less than about 20 wt. %, less than about 15 wt. %, less than about 10 wt. %, less than about 8 wt. %, less than about 6 wt. %, less than about 5 wt. %, less than about 4 wt. %, less than about 3 wt. %, less than about 2 wt. %, less than about 1 wt. %, less than about 0.5 wt. %, less than about 0.1 wt. %, or even less than about 0.01 wt. % of amorphous linaclotide.
- In exemplary embodiments, the present invention provides a composition comprising between about 50:50 and 99:1 α form linaclotide to amorphous linaclotide, such as, for example, between about 55:45 and 95:5 α form linaclotide to amorphous linaclotide, between about 60:40 and 90:10 α form linaclotide to amorphous linaclotide, between about 70:30 and 85:15 α form linaclotide to amorphous linaclotide, or even between about 75:25 and 99:1 α form linaclotide to amorphous linaclotide.
- Formulations and preparations that comprise the α form linaclotide described herein can be prepared in any suitable manner, such as described, for example, in the Handbook of Pharmaceutical Excipients, American Pharmaceutical Association (current edition); Pharmaceutical Dosage Forms: Tablets (Lieberman, Lachman and Schwartz, editors) current edition, published by Marcel Dekker, Inc., as well as Remington's Pharmaceutical Sciences (Arthur Osol, editor), 1553-1593 (current edition).
- Administration of the present invention can be accomplished in any suitable manner according to patient needs, for example, orally, nasally, parenterally (e.g., subcutaneously, intravenously, intramuscularly, intrasternally, and/or by infusion), by inhalation, rectally, vaginally, topically, and/or by ocular administration.
- Various dosage forms can be used for administering the present invention, such as any suitable oral dosage forms (e.g., solid oral dosage forms). In particular, for example, the present invention can be administered in the form of tablets, gelcaps, capsules, caplets, granules, lozenges and bulk powders. α form linaclotide can be administered alone or combined with various pharmaceutically acceptable carriers, diluents (such as sucrose, mannitol, lactose, starches) and excipients known in the art, including but not limited to suspending agents, solubilizers, buffering agents, binders, disintegrants, preservatives, colorants, flavorants, lubricants and the like. Time release capsules, tablets and gels are also advantageous in administering the compounds of the present invention.
- Various liquid oral dosage forms can also be used for administering α form linaclotide, including aqueous and non-aqueous solutions, emulsions, suspensions, syrups, and elixirs. Such dosage forms can also contain suitable inert diluents known in the art such as water and suitable excipients known in the art such as preservatives, wetting agents, sweeteners, flavorants, as well as agents for emulsifying and/or suspending the compounds of the invention. The α form linaclotide may be injected, for example, intravenously, in the form of an isotonic sterile solution.
- Suppositories for rectal administration of α form linaclotide can be prepared by mixing the compound with a suitable excipient such as cocoa butter, salicylates and polyethylene glycols.
- For topical administration, the pharmaceutical composition can be in the form of creams, ointments, liniments, lotions, emulsions, suspensions, gels, solutions, pastes, powders, sprays, and drops suitable for administration to the skin, eye, ear or nose. Topical administration may also involve transdermal administration via means such as transdermal patches.
- Aerosol formulations suitable for administering via inhalation also can be made. For example, for treatment of disorders of the respiratory tract, the compounds according to the invention can be administered by inhalation in the form of a powder (e.g., micronized) or in the form of atomized solutions or suspensions. The aerosol formulation can be placed into a pressurized acceptable propellant.
- The present invention provides methods of treating gastrointestinal disorders in a patient (e.g., mammal or human) diagnosed with one or more gastrointestinal disorders (such as, for example, irritable bowel syndrome, constipation-predominant irritable bowel syndrome, chronic constipation, opioid induced constipation and/or dyspepsia), wherein the method comprises administering an effective amount of α form linaclotide (or a composition comprising said α form linaclotide and optional additional components, additives, and/or species, as described herein) to said patient.
- In exemplary embodiments, the methods comprise administering a pharmaceutical composition comprising α form linaclotide and a pharmaceutically acceptable carriers and/or excipients.
- In exemplary embodiments, the methods comprise administering a pharmaceutical composition comprising α form linaclotide and a degradation product.
- In exemplary embodiments, the methods comprise administering a pharmaceutical composition comprising α form linaclotide and a hydrolysis product.
- In exemplary embodiments, the methods comprise administering a pharmaceutical composition comprising α form linaclotide and an acetylation product.
- In exemplary embodiments, the methods comprise administering a pharmaceutical composition comprising α form linaclotide and an oxidation product.
- In exemplary embodiments, the methods comprise administering a pharmaceutical composition comprising α form linaclotide and a formylation product.
- In exemplary embodiments, the methods comprise administering a pharmaceutical composition comprising α form linaclotide and a deamidation product.
- In exemplary embodiments, the methods comprise administering a pharmaceutical composition comprising α form linaclotide and a multimer product.
- In exemplary embodiments, the methods comprise administering a pharmaceutical composition comprising α form linaclotide and a dimer product.
- In exemplary embodiments, the methods comprise administering a pharmaceutical composition comprising α form linaclotide and an isomer product.
- An effective amount of α form linaclotide required to achieve desired results (such as desired treatment and/or symptom relief) of a subject is dependent on several understood factors, such as the identity and severity of the disorder being treated, as well as the age, weight, etc., of the patient being treated.
- A subject or patient in whom administration of the therapeutic compound is an effective therapeutic regimen for a disease or disorder is preferably a human, but can be any animal, including a laboratory animal in the context of a clinical trial or screening or activity experiment. Thus, as can be readily appreciated by one of ordinary skill in the art, the methods, compounds and compositions of the present invention are particularly suited to administration to any animal, particularly a mammal, and including, but by no means limited to, humans, domestic animals, such as feline or canine subjects, farm animals, such as but not limited to bovine, equine, caprine, ovine, and porcine subjects, wild animals (whether in the wild or in a zoological garden), research animals, such as mice, rats, rabbits, goats, sheep, pigs, dogs, cats, etc., avian species, such as chickens, turkeys, songbirds, etc., i.e., for veterinary medical use.
- In some embodiments, the compounds of the present invention are administered as a mono-therapy. In other embodiments, the compounds of the present invention are administered as part of a combination therapy. For example, a compound of the invention may be used in combination with other drugs or therapies that are used in the treatment/prevention/suppression and/or amelioration of the diseases or conditions for which compounds of the invention are useful.
- Such other drug(s) may be administered, by a route and in an amount commonly used therefore, contemporaneously or sequentially with a compound of the invention. When a compound of the present invention is used contemporaneously with one or more other drugs, a pharmaceutical unit dosage form containing such other drugs in addition to the compound of the invention may be employed. Accordingly, the pharmaceutical compositions of the present invention include those that also contain one or more other active ingredients, in addition to a compound of invention.
- The following examples are merely illustrative of the present invention and should not be construed as limiting the scope of the invention in any way as many variations and equivalents that are encompassed by the present invention will become apparent to those skilled in the art upon reading the present disclosure.
- 100 mg linaclotide was added to 10 ml aqueous acid solution (for example, 0.1N hydrochloric acid). The mixture was stirred using magnetic stirrer for 30-60 minutes at room temperature. The suspension was carefully filtered into a glass container and the filtrate was stored under room temperature conditions. After a suitable formation period, the α crystalline form of linaclotide was carefully isolated, washed, dried and analyzed using powder X-ray diffractometry.
FIG. 2 shows the X-ray diffraction pattern for the α crystalline form of linaclotide. - 100 mg linaclotide was added to 10 ml aqueous acid solution (for example, 0.1N hydrochloric acid). The mixture was stirred using magnetic stirrer for 10-60 minutes at temperature in the range of 20° C. to 65° C. The suspension was carefully filtered into a glass container and the filtrate was stored under room temperature conditions. After a suitable formation period, the crystalline form of linaclotide was carefully isolated, washed, dried and analyzed using powder X-ray diffractometry.
- 100 mg linaclotide was added to 10 ml aqueous acid solution (for example, 0.1N hydrochloric acid). The mixture was stirred using magnetic stirrer for 10-60 minutes at temperature in the range of 20° C. to 65° C. The suspension was carefully filtered into a glass container and the filtrate was stored at 4° C. After a suitable formation period, the crystalline form of linaclotide was carefully isolated, washed, dried and analyzed using powder X-ray diffractometry.
- 100 mg linaclotide was added to 10 ml aqueous acid solution (for example, 0.1N hydrochloric acid). The mixture was stirred using magnetic stirrer for 10-60 minutes at temperature in the range of 20° C. to 65° C. The suspension was carefully filtered into a glass container. A weighed amount of a salt (for example sodium chloride) was added to the filtrate and it was stored under room temperature conditions. After a suitable formation period, the crystalline form of linaclotide was carefully isolated, washed, dried and analyzed using powder X-ray diffractometry.
- 100 mg linaclotide was added to 10 ml aqueous acid solution (for example, 0.1N hydrochloric acid). The mixture was stirred using magnetic stirrer for 10-60 minutes at temperature in the range of 20° C. to 65° C. The suspension was carefully filtered into a glass container. A weighed amount of a salt (for example sodium chloride) was added to the filtrate and it was stored at 4° C. After a suitable formation period, the crystalline form of linaclotide was carefully isolated, washed, dried and analyzed using powder X-ray diffractometry.
- 100 mg linaclotide was added to 10 ml aqueous acid solution (for example, 0.1N hydrochloric acid) containing a known amount of polymer (for example, polyvinyl pyrrolidone). The mixture was shaken using an end-over-end shaker for 6-48 hours at temperature in the range of 20° C. to 65° C. The suspension was carefully filtered into a glass container. A weighed amount of a salt (for example sodium chloride) was added to the filtrate and it was stored at 4° C. After a suitable formation period, the crystalline form of linaclotide was carefully isolated, washed, dried and analyzed using powder X-ray diffractometry.
- The X-ray power diffraction patterns of the samples were determined in Example 1 using a wide-angle bench-top X-ray diffractometer (MiniFlex, Rigaku/MSC Inc., Woodlands, Tex.). The samples were loaded on zero background holders and exposed to CuKα radiation (30 kV×15 mA). The instrument was operated in the step-scan mode, in increments of 0.05°2θ. The angular range was 5 to 40°2θ, and the scan rate was 0.1°2θ/min. The data collection and analyses were performed with commercially available software (JADE, version 7.1, Materials Data, Inc., Livermore, Calif.).
- The α-crystalline forms of linaclotide that were prepared in Examples 1A-1F were prepared and analyzed in this Example using a second wide-angle bench-top X-ray diffractometer (Model D8, Bruker AXS Inc., Madison Wis.). A small amount of the samples was loaded on a zero background holder and exposed to CuKα radiation (40 kV×40 mA) in the wide-angle bench-top X-ray diffractometer (Model D8, Bruker AXS Inc., Madison Wis.). The instrument was operated in the step-scan mode, in increments of 0.05°2θ. The angular range was 5 to 30°2θ, and the scan rate ranged from 0.05-0.1°2θ/min. The data collection and analyses were performed with commercially available software (JADE, version 7.1, Materials Data, Inc., Livermore, Calif.).
- 100 mg linaclotide was mixed with 0.1N hydrochloric acid. The mixture was stirred using magnetic stirrer for 30-60 minutes at room temperature. The suspension was carefully filtered into a glass container and the filtrate was stored under room conditions. After a suitable formation period, the α crystalline form of linaclotide was carefully isolated, washed, dried and analyzed using powder X-ray diffractometry.
FIG. 3 shows the X-ray powder diffraction pattern for the crystalline form of linaclotide. Peak positions for the XRD are provided in Table 1. -
TABLE 1 2-Theta (°) d(Å) 5.7 15.6 6.1 14.6 7.0 12.5 7.7 11.4 8.2 10.8 8.5 10.4 9.6 9.2 10.2 8.7 11.0 8.0 11.3 7.8 11.8 7.5 12.2 7.2 12.6 7.0 13.7 6.5 14.3 6.2 15.0 5.9 15.5 5.7 16.0 5.5 16.4 5.4 17.1 5.2 17.9 4.9 18.5 4.8 19.0 4.7 19.4 4.6 19.8 4.5 20.3 4.4 20.8 4.3 21.5 4.1 22.5 3.9 23.1 3.8 23.8 3.7 24.2 3.7 24.5 3.6 25.5 3.5 26.1 3.4 26.5 3.4 27.5 3.2 28.2 3.2 28.8 3.1 29.2 3.1 29.6 3.0 - The α form linaclotide was also analyzed via Fourier Transform infrared spectroscopy by loading a small sample of the α form linaclotide (approx. 1 mg) onto a Durascope™ diamond stage and exposing it to an IR beam in the FT-IR spectrometer using attenuated total diffuse reflectance (ATR) mode. All spectra were run at 4000-525 cm−1 wavenumbers, 300 scans and 2 cm−1 resolution. The Fourier Transform infrared spectrum for the α form linaclotide is shown in
FIG. 4 . - The α form linaclotide was also analyzed using a differential scanning calorimeter (MDSC Q1000, TA Instruments, New Castle, Del.) with a refrigerated cooling accessory. The instrument was calibrated with pure samples of indium. About 2-5 mg sample was weighed in open non-hermetic aluminum pans with a cover lid and heated under dry nitrogen purge (flow
rate 50 ml/min) at 10° C./min. The data was analyzed using Universal Analysis 2000 (TA instruments, New Castle, Del.). The DSC thermogram of the α form linaclotide is shown inFIG. 5 . - 100 mg linaclotide was mixed with 0.1N hydrochloric acid. The mixture was stirred using magnetic stirrer for 10-60 minutes at temperature in the range of 20° C. to 65° C. The suspension was carefully filtered into a glass container and the filtrate was stored under room conditions. After a suitable formation period, the α crystalline form of linaclotide was carefully isolated, washed, dried and analyzed using powder X-ray diffractometry.
FIG. 6 shows the X-ray powder diffraction pattern for the crystalline form of linaclotide. Peak positions for the XRD are provided in Table 2. -
TABLE 2 2-Theta (°) d(Å) 5.7 15.5 6.0 14.6 6.3 14.0 7.7 11.5 8.1 10.9 8.4 10.5 9.0 9.9 9.5 9.3 10.1 8.8 10.5 8.4 10.9 8.1 11.4 7.8 11.7 7.6 12.1 7.3 12.4 7.1 12.9 6.8 13.6 6.5 14.2 6.2 14.7 6.0 14.9 5.9 15.4 5.8 15.9 5.6 17.0 5.2 17.8 5.0 18.1 4.9 19.6 4.5 20.2 4.4 20.6 4.3 21.3 4.2 22.5 3.9 23.8 3.7 24.4 3.6 25.1 3.5 26.0 3.4 26.5 3.4 27.1 3.3 27.7 3.2 28.7 3.1 - 100 mg linaclotide was mixed with 0.1N hydrochloric acid. The mixture was stirred using magnetic stirrer for 10-60 minutes at temperature in the range of 20° C. to 65° C. The suspension was carefully filtered into a glass container and the filtrate was stored at 4° C. After a suitable formation period, the α crystalline form of linaclotide was carefully isolated, washed, dried and analyzed using powder X-ray diffractometry.
FIG. 7 shows the X-ray powder diffraction pattern for the crystalline form of linaclotide. Peak positions for the XRD are provided in Table 3. -
TABLE 3 2-Theta (°) d(Å) 5.8 15.3 6.1 14.5 6.4 13.9 7.7 11.5 8.4 10.5 9.4 9.4 10.5 8.4 11.5 7.7 12.9 6.9 13.6 6.5 14.1 6.3 14.9 6.0 15.4 5.7 15.9 5.6 16.2 5.5 17.4 5.1 18.2 4.9 18.8 4.7 19.4 4.6 19.6 4.5 20.4 4.3 20.7 4.3 22.5 3.9 22.7 3.9 23.3 3.8 23.9 3.7 25.5 3.5 25.7 3.5 27.6 3.5 - 100 mg linaclotide was mixed with 0.1N hydrochloric acid. The mixture was stirred using magnetic stirrer for 10-60 minutes at temperature in the range of 20° C. to 65° C. The suspension was carefully filtered into a glass container. A weighed amount of sodium chloride was added to the filtrate and it was stored under room conditions. After a suitable formation period, the α crystalline form of linaclotide was carefully isolated, washed, dried and analyzed using powder X-ray diffractometry.
FIG. 8 shows the X-ray powder diffraction pattern for the crystalline form of linaclotide. Peak positions for the XRD are provided in Table 4. -
TABLE 4 2-Theta (°) d(Å) 5.6 15.6 6.0 14.7 7.7 11.5 8.1 10.9 8.4 10.5 9.5 9.3 10.1 8.8 11.0 8.0 11.2 7.9 11.8 7.5 12.2 7.3 12.5 7.1 13.6 6.5 14.1 6.3 14.6 6.0 14.9 5.9 15.4 5.8 15.9 5.6 16.3 5.4 17.0 5.2 17.8 5.0 18.1 4.9 18.7 4.7 19.4 4.6 20.2 4.4 20.7 4.3 21.1 4.2 21.5 4.1 22.5 4.0 23.1 3.8 23.4 3.8 23.8 3.7 24.4 3.6 25.1 3.5 25.4 3.5 - 100 mg linaclotide was mixed with 0.1N hydrochloric acid. The mixture was stirred using magnetic stirrer for 10-60 minutes at temperature in the range of 20° C. to 65° C. The suspension was carefully filtered into a glass container. A weighed amount of sodium chloride was added to the filtrate and it was stored at 4° C. After a suitable formation period, the α crystalline form of linaclotide was carefully isolated, washed, dried and analyzed using powder X-ray diffractometry.
FIG. 9 shows the X-ray powder diffraction pattern for the crystalline form of linaclotide. Peak positions for the XRD are provided in Table 5. -
TABLE 5 2-Theta (°) d(Å) 5.6 15.6 6.0 14.7 7.7 11.5 8.1 10.9 8.4 10.5 9.5 9.3 10.1 8.8 11.0 8.0 11.2 7.9 11.8 7.5 12.2 7.3 12.5 7.1 13.6 6.5 14.1 6.3 14.9 5.9 15.4 5.8 15.9 5.6 16.3 5.4 17.0 5.2 17.8 5.0 18.1 4.9 19.4 4.6 20.2 4.4 20.7 4.3 21.1 4.2 21.5 4.1 22.5 4.0 23.1 3.8 23.4 3.8 23.8 3.7 24.4 3.6 25.1 3.5 25.4 3.5 27.1 3.3 - 100 mg linaclotide was mixed with 0.1N hydrochloric acid containing a known amount of polymer (for example, polyvinyl pyrrolidone). The mixture was shaken using an end-over-end shaker for 6-48 hours at temperature in the range of 20° C. to 65° C. The suspension was carefully filtered into a glass container. A weighed amount of sodium chloride was added to the filtrate and it was stored at 4° C. After a suitable formation period, the α crystalline form of linaclotide was carefully isolated, washed, dried and analyzed using powder X-ray diffractometry.
FIG. 10 shows the X-ray powder diffraction pattern for the crystalline form of linaclotide. Peak positions for the XRD are provided in Table 6. -
TABLE 6 2-Theta (°) d(Å) 6.1 14.5 7.7 11.5 8.2 10.7 8.5 10.4 10.2 8.7 11.2 7.9 12.3 7.2 13.7 6.4 14.2 6.2 16.0 5.5 16.4 5.4 17.9 4.9 19.5 4.5 20.4 4.3 20.9 4.2 22.5 3.9 23.9 3.7 24.2 3.7 25.5 3.5 27.3 3.3 27.6 3.2 - 100 mg linaclotide was mixed with 0.1N nitric acid. The mixture was stirred using magnetic stirrer for 30-60 minutes at room temperature. The suspension was carefully filtered into a glass container and the filtrate was stored under room temperature conditions. After a suitable formation period, the α crystalline form of linaclotide was carefully isolated, washed, dried and analyzed using powder X-ray diffractometry.
FIG. 11 shows the X-ray powder diffraction pattern for the crystalline form of linaclotide. Peak positions for the XRD are provided in Table 7. -
TABLE 7 2-Theta (°) d(Å) 5.6 15.6 6.0 14.7 6.3 14.0 7.7 11.5 8.1 10.9 8.4 10.5 9.5 9.3 10.1 8.8 11.0 8.1 11.2 7.9 11.8 7.5 12.2 7.3 12.5 7.1 13.6 6.5 14.2 6.2 14.9 6.0 15.4 5.8 15.9 5.6 16.3 5.4 17.0 5.2 17.8 5.0 18.9 4.7 19.4 4.6 20.2 4.4 20.7 4.3 21.4 4.1 22.4 4.0 23.8 3.7 24.4 3.6 25.4 3.5 - 100 mg linaclotide was mixed with 0.1N methane sulfonic acid. The mixture was stirred using magnetic stirrer for 30-60 minutes at room temperature. The suspension was carefully filtered into a glass container and the filtrate was stored under room temperature conditions. After a suitable formation period, the α crystalline form of linaclotide was carefully isolated, washed, dried and analyzed using powder X-ray diffractometry.
FIG. 12 shows the X-ray powder diffraction pattern for the crystalline form of linaclotide. Peak positions for the XRD are provided in Table 8. -
TABLE 8 2-Theta (°) d(Å) 5.6 15.7 6.0 14.7 6.3 14.0 7.7 11.5 8.1 10.9 8.5 10.5 9.5 9.3 10.1 8.8 10.6 8.4 11.2 7.9 11.7 7.6 12.1 7.3 12.5 7.1 13.6 6.5 14.1 6.3 14.6 6.1 14.8 6.0 15.4 5.7 15.9 5.6 16.3 5.4 17.0 5.2 17.8 5.0 18.1 4.9 18.9 4.7 19.3 4.6 19.7 4.5 20.2 4.4 20.7 4.3 21.1 4.2 21.5 4.1 22.5 4.0 23.1 3.8 23.7 3.7 24.1 3.7 25.3 3.5 - 100 mg linaclotide was mixed with 0.1N hydrobromic acid. The mixture was stirred using magnetic stirrer for 30-60 minutes at room temperature. The suspension was carefully filtered into a glass container and the filtrate was stored under room conditions. After a suitable formation period, the α crystalline form of linaclotide was carefully isolated, washed, dried and analyzed using powder X-ray diffractometry.
FIG. 13 shows the X-ray powder diffraction pattern for the crystalline form of linaclotide. Peak positions for the XRD are provided in Table 9. -
TABLE 9 2-Theta (°) d(Å) 5.6 15.8 6.0 14.8 7.0 12.6 7.7 11.5 8.1 10.9 8.4 10.5 9.5 9.3 10.1 8.7 11.2 7.9 11.7 7.5 12.2 7.3 12.4 7.1 13.6 6.5 14.2 6.2 14.6 6.1 14.9 6.0 15.3 5.8 15.8 5.6 16.3 5.4 16.6 5.3 16.9 5.2 17.7 5.0 18.0 4.9 18.4 4.8 18.7 4.7 18.9 4.7 19.3 4.6 19.7 4.5 20.1 4.4 20.7 4.3 21.4 4.1 21.7 4.1 22.4 4.0 23.0 3.9 23.3 3.8 23.7 3.8 24.1 3.7 24.4 3.6 25.0 3.6 25.3 3.5 - The relative chemical purity and stability of amorphous and crystalline linaclotide was studied using reverse phase high performance liquid chromatography (HPLC). The chemical identification was conducted using reverse phase high performance liquid chromatography coupled with mass spectroscopy (HPLC-MS). The mass spectroscopic analysis was performed at Enhance MS scan (EMS) mode with positive ionization and a scan range (m/z) of 600-1600.
- A
Perkin Elmer series 200 LC instrument (Perkin Elmer, Waltham, Mass.) was used with a YMC Pro C18 column (150 mm×3.0 mm, 3 μm) (Waters Corporation, Milford, Mass.). The column temperature was set at 40° C. while the auto sampler temperature was maintained at 4° C. using a peltier tray. The injection volume was 50 μl. A gradient (0.6 ml/minute) run was used comprising of two solvents; A (97.9% Water, 2% Acetonitrile, 0.1% Trifluoroacetic Acid) and B (94.9% Acetonitrile, 5% Water, 0.1% Trifluoroacetic Acid). The gradient was set according to the scheme described in Table 10. The effluent was detected at 220 nm using a UV detector. -
TABLE 10 Gradient scheme for HPLC method TIME (MINUTES) % A % B COMMENTS 0 100 0 Initial Conditions 4 100 0 4-minute hold 9 90 10 5-minute linear gradient 43 77 23 34-minute linear gradient 49 66 34 6-minute linear gradient 59 20 80 10-minute linear gradient 60 100 0 Return to initial conditions 67 100 0 Re-equilibration - A
Perkin Elmer Series 200 LC-MS instrument (Perkin Elmer, Waltham, Mass.) was used with a Pursuit XR C18 column (150×2 mm, 3 μm). The column temperature was set at 40° C. while the autosampler temperature was maintained at 4° C. using a peltier tray. The injection volume was 5 μl. A gradient (0.25 ml/minute) run was used comprising of two solvents; A (0.1% trifluoroacetic acid in water) and B (0.1% trifluoroacetic acid in acetonitrile). The gradient was set according to the scheme described in Table 11. The effluent was detected at 220 nm using a UV detector. The mass spectroscopic analysis was performed at Enhance MS scan (EMS) mode with positive ionization and a scan range (m/z) of 600-1600. -
TABLE 11 Gradient scheme for HPLC-MS method TIME (MINUTES) % A % B COMMENTS 0 95 5 Initial Conditions 5 95 5 5- minute hold 10 85 15 5-minute linear gradient 40 75 25 30-minute linear gradient 50 65 35 10-minute linear gradient 60 25 75 10-minute linear gradient 60.1 95 5 Return to initial conditions 70 95 5 Re-equilibration - The precipitates prepared in Examples 1A and 2A were chemically identified as linaclotide based on HPLC-MS analysis. The purity of the precipitate was found to be in the range of 95% to 100%,
- The solid-state chemical stability of the α-crystalline form of linaclotide was then compared to that of amorphous form linaclotide. Known quantities of test materials were placed in 45 cc high-density polyethylene bottles. The bottles were induction sealed and placed in 40° C./75% RH stability chamber. Two bottles were then withdrawn at the time points of 2 weeks, at 1 month, at 2 months, and at 3 months, and were analyzed after adequate dilution for assay. The normalized assay results are shown in Table 12.
-
TABLE 12 Solid-State chemical stability of amorphous and α-crystalline form of linaclotide Amorphous Linaclotide α-Crystalline Linaclotide Normalized Degradation Normalized Degradation Assay Products Assay Products Time (Wt %) (Wt %) (Wt %) (Wt %) Initial 100.0 2.1 100.0 2.4 2 Weeks 84.0 3.6 94.8 2.6 1 Month 79.1 5.6 91.9 3.8 2 Months 74.5 9.3 89.7 5.1 3 Months 68.8 12.0 88.4 7.5 - The remaining 19.2% and 4.1% of the amorphous and α-form linaclotide respectively may comprise multimers.
- As is illustrated in Table 12, the α-crystalline form of linaclotide was found to have a substantially better stability profile than amorphous linaclotide, under the study conditions. Additionally, as is illustrated, the α-crystalline form of linaclotide had a significantly lower concentration of degradation products, as well as significantly less multimer formation.
- As is illustrated in Table 13, the α-crystalline form of linaclotide was also found to have lower concentrations of degradation products (water mediated de-amidation and hydrolysis) and non-disulfide linked multimers as compared to amorphous linaclotide after storage for three months in induction sealed 45 cc high-density polyethylene bottles at 40° C./75% RH. On the other hand, acid-induced hydrolysis was pronounced in the crystalline form.
-
TABLE 13 Degradation Profile following 3 months storage in induction sealed 45 cc high-density polyethylene bottles under 40° C./75% RH Degradation Products Water- Non-disulfide Hydrolysis Mediated Acetylation linked Product Products Product multimers (Wt %) (Wt %) (Wt %) (Wt %) Amorphous 0.30 7.00 2.39 1.96 linaclotide Crystalline 5.70 0.40 0.31 0.07 linaclotide - A linaclotide hydrolysis product was prepared by transforming Asn in the 7 position to Asp (the numbering of linaclotide starts with 1 at the N-terminal Cys). The linaclotide hydrolysis product was synthesized using a solid phase peptide synthesis technique. The structure of the linaclotide hydrolysis product is shown below:
- The linaclotide hydrolysis product may also be prepared by other methods known in the art, e.g., by isolation from linaclotide preparations using chromatographic techniques or by recombinant expression of a nucleic acid encoding the linaclotide hydrolysis product (CCEYCCDPACTGCY), optionally followed by oxidation of the cysteine residues to form the disulfide linkages.
- While the invention has been depicted and described by reference to exemplary embodiments of the invention, such a reference does not imply a limitation on the invention, and no such limitation is to be inferred. The invention is capable of considerable modification, alteration, and equivalents in form and function, as will occur to those ordinarily skilled in the pertinent arts having the benefit of this disclosure.
- As is demonstrated in the Examples, and as is discussed in this application, the crystalline forms of linaclotide have physical properties (e.g., stability properties) that are surprising and unexpected as compared to amorphous linaclotide and/or other crystalline forms of linaclotide. The crystalline forms of linaclotide may also have synergy with other active or inactive components resulting in enhanced performance characteristics or properties of pharmaceutical compositions comprising one or more crystalline forms of the present invention.
- The depicted and described embodiments of the invention are exemplary only, and are not exhaustive of the scope of the invention. Consequently, the invention is intended to be limited only by the spirit and scope of the appended claims, giving full cognizance to equivalence in all respects.
- All references cited herein are hereby incorporated by reference in their entirety.
Claims (18)
1. An α-crystalline form of linaclotide.
2. The crystalline form of claim 1 , having an X-ray powder diffraction pattern comprising peaks at about 7.8 and about 23.9+/−0.5 degrees 2θ.
3. The crystalline form of claim 1 , having an X-ray powder diffraction pattern having peaks at about 6.2, about 7.8 and about 23.9+/−0.5 degrees 2θ.
4. The crystalline form of claim 1 , having an X-ray powder diffraction pattern having peaks at about 6.2, about 7.8, about 19.5, about 22.6, and about 23.9+/−0.5 degrees 2θ.
5. The crystalline form of claim 1 , having an X-ray powder diffraction pattern substantially as shown in FIG. 2 .
6. A crystalline form of linaclotide, having an X-ray powder diffraction pattern comprising peaks at about 5.7, about 7.7 and about 23.8+/−0.5 degrees 2θ.
7. The crystalline form of claim 6 , wherein the X-ray powder diffraction pattern further comprises a peak at about 19.4+/−0.5 degrees 2θ and/or a peak at about 22.5+/−0.5 degrees 2θ.
8. The crystalline form of claim 6 , wherein the X-ray powder diffraction pattern further comprises peaks at about 19.4 and at about 22.5+/−0.5 degrees 2θ.
9. The crystalline form of claim 6 , having an X-ray powder diffraction pattern further comprising d spacing peaks at about 3.7, about 11.5 and about 15.5+/—0.5 angstroms.
10. A pharmaceutical composition comprising the crystalline form of claim 1 .
11. A pharmaceutical composition comprising the crystalline form of claim 6 .
12. A process for preparing an α-crystalline form of linaclotide, comprising crystallizing linaclotide to form an α-crystalline form of linaclotide and optionally isolating the α-crystalline form of linaclotide.
13. A method of treating a gastrointestinal disorder comprising administering to a patient in need thereof, the crystalline form of claim 1 .
14. The method of claim 13 , wherein the gastrointestinal disorder is constipation-predominant irritable bowel syndrome.
15. The method of claim 13 , wherein the gastrointestinal disorder is chronic constipation.
16. A method of treating a gastrointestinal disorder comprising administering to a patient in need thereof, the crystalline form of claim 6 .
17. The method of claim 16 , wherein the gastrointestinal disorder is constipation-predominant irritable bowel syndrome.
18. The method of claim 16 , wherein the gastrointestinal disorder is chronic constipation.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13/586,303 US20120309695A1 (en) | 2008-11-19 | 2012-08-15 | Crystalline form of linaclotide |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11615608P | 2008-11-19 | 2008-11-19 | |
US12/621,272 US8222201B2 (en) | 2008-11-19 | 2009-11-18 | Crystalline form of linaclotide |
US13/458,031 US8293704B2 (en) | 2008-11-19 | 2012-04-27 | Crystalline form of linaclotide |
US13/586,303 US20120309695A1 (en) | 2008-11-19 | 2012-08-15 | Crystalline form of linaclotide |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/458,031 Continuation US8293704B2 (en) | 2008-11-19 | 2012-04-27 | Crystalline form of linaclotide |
Publications (1)
Publication Number | Publication Date |
---|---|
US20120309695A1 true US20120309695A1 (en) | 2012-12-06 |
Family
ID=42172504
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/621,272 Active 2030-11-05 US8222201B2 (en) | 2008-11-19 | 2009-11-18 | Crystalline form of linaclotide |
US13/458,031 Active US8293704B2 (en) | 2008-11-19 | 2012-04-27 | Crystalline form of linaclotide |
US13/586,303 Abandoned US20120309695A1 (en) | 2008-11-19 | 2012-08-15 | Crystalline form of linaclotide |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/621,272 Active 2030-11-05 US8222201B2 (en) | 2008-11-19 | 2009-11-18 | Crystalline form of linaclotide |
US13/458,031 Active US8293704B2 (en) | 2008-11-19 | 2012-04-27 | Crystalline form of linaclotide |
Country Status (6)
Country | Link |
---|---|
US (3) | US8222201B2 (en) |
EP (1) | EP2365821A4 (en) |
JP (1) | JP2012509281A (en) |
CA (1) | CA2743172A1 (en) |
MX (1) | MX2011005245A (en) |
WO (1) | WO2010059733A1 (en) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2166008A1 (en) * | 2008-09-23 | 2010-03-24 | Genkyo Tex Sa | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors |
EP2165707A1 (en) * | 2008-09-23 | 2010-03-24 | Genkyo Tex Sa | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors |
WO2010059733A1 (en) * | 2008-11-19 | 2010-05-27 | Forest Laboratories Holdings Limited | Crystalline form of linaclotide |
JP2016521249A (en) * | 2012-07-12 | 2016-07-21 | フォレスト ラボラトリーズ ホールディングス リミテッド | Linaclotide composition |
EP2950803A1 (en) | 2013-01-30 | 2015-12-09 | Sandoz AG | Crystalline form of linaclotide |
CN104844693B (en) * | 2015-06-10 | 2018-08-03 | 成都圣诺生物科技股份有限公司 | A method of synthesis Linaclotide |
US10889620B2 (en) | 2015-07-01 | 2021-01-12 | Novetide Ltd. | Solid state forms of linaclotide |
CN107163105B (en) * | 2017-06-28 | 2020-12-11 | 清华大学 | Crystallization method of natural linaclotide |
EP4194464A1 (en) * | 2021-12-13 | 2023-06-14 | Chemi SPA | Manufacturing process for the production of linaclotide |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002081129A1 (en) * | 2001-04-02 | 2002-10-17 | Mitsubishi Materials Corporation | Composite soft magnetic sintered material having high density and high magnetic permeability and method for preparation thereof |
US7304036B2 (en) * | 2003-01-28 | 2007-12-04 | Microbia, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
EP1594517B1 (en) | 2003-01-28 | 2007-06-20 | Microbia, Inc. | Compositions for the treatment of gastrointestinal disorders |
US7371727B2 (en) * | 2003-01-28 | 2008-05-13 | Microbia, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
US7772188B2 (en) * | 2003-01-28 | 2010-08-10 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
US20060281682A1 (en) | 2003-01-28 | 2006-12-14 | Currie Mark G | Methods and compositions for the treatment of gastrointestinal disorders |
EP3342420A1 (en) | 2003-06-13 | 2018-07-04 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
WO2007005780A2 (en) * | 2005-07-01 | 2007-01-11 | Dynogen Pharmaceuticals, Inc. | Compositions and methods for treating gastrointestinal hypomotility and associated disorders |
PE20090696A1 (en) * | 2007-04-20 | 2009-06-20 | Bristol Myers Squibb Co | CRYSTALLINE FORMS OF SAXAGLIPTIN AND PROCESSES FOR PREPARING THEM |
MX2009011898A (en) | 2007-05-04 | 2009-11-18 | Ironwood Pharmaceuticals Inc | Compositions and methods for treating disorders associated with salt or fluid retention. |
WO2010059733A1 (en) * | 2008-11-19 | 2010-05-27 | Forest Laboratories Holdings Limited | Crystalline form of linaclotide |
-
2009
- 2009-11-18 WO PCT/US2009/065001 patent/WO2010059733A1/en active Application Filing
- 2009-11-18 CA CA2743172A patent/CA2743172A1/en not_active Abandoned
- 2009-11-18 US US12/621,272 patent/US8222201B2/en active Active
- 2009-11-18 MX MX2011005245A patent/MX2011005245A/en active IP Right Grant
- 2009-11-18 JP JP2011536620A patent/JP2012509281A/en active Pending
- 2009-11-18 EP EP09828173.6A patent/EP2365821A4/en not_active Withdrawn
-
2012
- 2012-04-27 US US13/458,031 patent/US8293704B2/en active Active
- 2012-08-15 US US13/586,303 patent/US20120309695A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US8222201B2 (en) | 2012-07-17 |
MX2011005245A (en) | 2011-06-17 |
WO2010059733A1 (en) | 2010-05-27 |
EP2365821A4 (en) | 2013-09-04 |
US8293704B2 (en) | 2012-10-23 |
EP2365821A1 (en) | 2011-09-21 |
JP2012509281A (en) | 2012-04-19 |
CA2743172A1 (en) | 2010-05-27 |
US20120214750A1 (en) | 2012-08-23 |
US20100125056A1 (en) | 2010-05-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8293704B2 (en) | Crystalline form of linaclotide | |
CN112638904A (en) | Solid forms of 2- (3, 5-dichloro-4- ((5-isopropyl-6-oxo-1, 6-dihydropyridazin-3-yl) oxy) phenyl) -3, 5-dioxo-2, 3,4, 5-tetrahydro-1, 2, 4-triazine-6-carbonitrile | |
US9259403B2 (en) | Crystalline forms of (1S,2R)-2-(amino methyl)-N,N-diethyl-1-phenyl cyclopropane carboxamide | |
US20240043465A1 (en) | Co-crystal forms of a novobiocin analog and proline | |
HUE030930T2 (en) | Sulphate salts of n-(3-(4-(3-(diisobutylamino)propyl)piperazin-1-yl)propyl)-1h-benzo[d]imidazol-2-amine, preparation thereof and use of the same | |
KR101800140B1 (en) | Benzothiazolone compound | |
AU2008334941B2 (en) | Advantageous salts of mu-opiate receptor peptides | |
US20210094961A1 (en) | Form of ponatinib | |
DK2890687T3 (en) | Salts of benzothiazolone compound as beta-2-adrenoceptor agonist | |
US20220298158A1 (en) | Polymorph of venetoclax and method for preparing the polymorph | |
US20210032235A1 (en) | Crystalline forms of dasatinib | |
US20210395232A1 (en) | Co-crystal forms of selinexor | |
JP2023524622A (en) | 6-chloro-7-(4-(4-chlorobenzyl)piperazin-1-yl)-2-(1,3-dimethyl-1H-pyrazol-4-yl)-3H-imidazo[4,5-b] Salts and polymorphs of pyridine | |
EA043335B1 (en) | FORMS OF CO-CRYSTALS OF ANALOGUE OF NOVOBIOCIN AND PROLINE | |
NZ621089B2 (en) | Benzothiazolone compound |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |